

論文業績一覧

1. 一元化登録（2009年4月以降）データ利用申請・WG研究 論文業績

	論文タイトル	著者	雑誌名	発行年	刊・号・頁	業績番号
1	小児へのさい帯血移植.	加藤剛二.	日本さい帯血バンクネットワーク設立10周年記念 そして明日から	2009	54-7.	U1
2	Pre-transplant imatinib-based therapy improves the outcome of allogeneic hematopoietic stem cell transplantation for BCR-ABL-positive acute lymphoblastic leukemia.	Mizuta S, Matsuo K, Yagasaki F, Yujiri T, Hatta Y, Kimura Y, Ueda Y, Kanamori H, Usui N, Akiyama H, Miyazaki Y, Ohtake S, Atsuta Y, Sakamaki H, Kawa K, Morishima Y, Ohnishi K, Naoe T, Ohno R.	Leukemia	2011	25(1):41-7.	U2
3	A suggested total size for the cord blood banks of Japan.	Takanashi M, Tanaka H, Kohsaki M, Nakajima K, Tadokoro K, Nakabayashi M.	Bone Marrow Transplant	2011	46(7):1014-5.	U3
4	Successful cord blood transplantation in a 42-day-old boy with infantile Krabbe disease.	Yagasaki H, Kato M, Ishige M, Shichino H, Chin M, Mugishima H.	Int J Hematol	2011	93(4):566-8.	U4
5	Allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with t(6;9)(p23;q34) dramatically improves the patient prognosis: a matched-pair analysis.	Ishiyama K, Takami A, Kanda Y, Nakao S, Hidaka M, Maeda T, Naoe T, Taniguchi S, Kawa K, Nagamura T, Atsuta Y, Sakamaki H.	Leukemia	2012	26(3):461-4.	U5
6	Prognostic factors for acute myeloid leukemia patients with t(6;9)(p23;q34) who underwent an allogeneic hematopoietic stem cell transplant.	Ishiyama K, Takami A, Kanda Y, Nakao S, Hidaka M, Maeda T, Naoe T, Taniguchi S, Kawa K, Nagamura T, Tabuchi K, Atsuta Y, Sakamaki H.	Leukemia	2012	26(6):1416-9.	U6
7	Peripheral blood as a preferable source of stem cells for salvage transplantation in patients with graft failure after cord blood transplantation: a retrospective analysis of the registry data of the Japanese Society for Hematopoietic Cell Transplantation.	Fuji S, Nakamura F, Hatanaka K, Taniguchi S, Sato M, Mori S, Sakamaki H, Yabe H, Miyamoto T, Kanamori H, Ueda Y, Kawa K, Kato K, Suzuki R, Atsuta Y, Tamaki T, Kanda Y.	Biol Blood Marrow Transplant	2012	18(9):1407-14.	U7
8	Impact of graft-versus-host disease on outcomes after allogeneic hematopoietic cell transplantation for adult T-cell leukemia: a retrospective cohort study.	Kanda J, Hishizawa M, Utsunomiya A, Taniguchi S, Eto T, Moriuchi Y, Tanosaki R, Kawano F, Miyazaki Y, Masuda M, Nagafuji K, Hara M, Takanashi M, Kai S, Atsuta Y, Suzuki R, Kawase T, Matsuo K, Nagamura-Inoue T, Kato S, Sakamaki H, Morishima Y, Okamura J, Ichinohe T, Uchiyama T.	Blood	2012	119(9):2141-8.	U8
9	Related transplantation with HLA-1 Ag mismatch in the GVH direction and HLA-8/8 allele-matched unrelated transplantation: a nationwide retrospective study.	Kanda J, Saji H, Fukuda T, Kobayashi T, Miyamura K, Eto T, Kurokawa M, Kanamori H, Mori T, Hidaka M, Iwato K, Yoshida T, Sakamaki H, Tanaka J, Kawa K, Morishima Y, Suzuki R, Atsuta Y, Kanda Y.	Blood	2012	119(10):2409-16.	U9

10	Efficacy and long-term outcome of treatment for pure red cell aplasia after allogeneic stem cell transplantation from major ABO-incompatible donors.	Hirokawa M, Fukuda T, Ohashi K, Hidaka M, Ichinohe T, Iwato K, Kanamori H, Murata M, Sakura T, Imamura M, Adachi S, Suzuki R, Morishima Y, Sakamaki H; PRCA Collaborative Study Group.	Biol Blood Marrow Transplant	2013	19(7):1026-32.	U10
11	Changes in incidence and causes of non-relapse mortality after allogeneic hematopoietic cell transplantation in patients with acute leukemia/myelodysplastic syndrome: an analysis of the Japan Transplant Outcome Registry.	Kurosawa S, Yakushijin K, Yamaguchi T, Atsuta Y, Nagamura-Inoue T, Akiyama H, Taniguchi S, Miyamura K, Takahashi S, Eto T, Ogawa H, Kurokawa M, Tanaka J, Kawa K, Kato K, Suzuki R, Morishima Y, Sakamaki H, Fukuda T.	Bone Marrow Transplant	2013	48(4):529-36.	U11
12	Recent decrease in non-relapse mortality due to GVHD and infection after allogeneic hematopoietic cell transplantation in non-remission acute leukemia.	Kurosawa S, Yakushijin K, Yamaguchi T, Atsuta Y, Nagamura-Inoue T, Akiyama H, Taniguchi S, Miyamura K, Takahashi S, Eto T, Ogawa H, Kurokawa M, Tanaka J, Kawa K, Kato K, Suzuki R, Morishima Y, Sakamaki H, Fukuda T.	Bone Marrow Transplant	2013	48(9):1198-204.	U12
13	PBSCT is associated with poorer survival and increased chronic GvHD than BMT in Japanese paediatric patients with acute leukaemia and an HLA-matched sibling donor.	Shinzato A, Tabuchi K, Atsuta Y, Inoue M, Inagaki J, Yabe H, Koh K, Kato K, Ohta H, Kigasawa H, Kitoh T, Ogawa A, Takahashi Y, Sasahara Y, Kato S, Adachi S.	Pediatr Blood Cancer	2013	60(9):1513-9.	U13
14	Allogeneic hematopoietic stem cell transplantation for intermediate cytogenetic risk AML in first CR.	Imahashi N, Suzuki R, Fukuda T, Kakihana K, Kanamori H, Eto T, Mori T, Kobayashi N, Iwato K, Sakura T, Ikegame K, Kurokawa M, Kondo T, Iida H, Sakamaki H, Tanaka J, Kawa K, Morishima Y, Atsuta Y, Miyamura K.	Bone Marrow Transplant	2013	48(1):56-62.	U14
15	Feasibility of reduced-intensity conditioning followed by unrelated cord blood transplantation for primary hemophagocytic lymphohistiocytosis: a nationwide retrospective analysis in Japan.	Sawada A, Ohga S, Ishii E, Inoue M, Okada K, Inagaki J, Goto H, Suzuki N, Koike K, Atsuta Y, Suzuki R, Yabe H, Kawa K, Kato K, Yasutomo K.	Int J Hematol	2013	98(2):223-30.	U15
16	移植に必要なAB型の血漿・血小板製剤の需給動向について.	永澤雅秀.	血液事業	2013	35(4):703-5.	U16
17	Association between decreasing trend in the mortality of adult T-cell leukemia/lymphoma and allogeneic hematopoietic stem cell transplants in Japan: analysis of Japanese vital statistics and Japan Society for Hematopoietic Cell Transplantation (JSHCT).	Chihara D, Ito H, Matsuda T, Katanoda K, Shibata A, Taniguchi S, Utsunomiya A, Sobue T, Matsuo K.	Blood Cancer J	2013	3:e159.	U17
18	Granulocyte colony-stimulating factor combined regimen in cord blood transplantation for acute myeloid leukemia: a nationwide retrospective analysis in Japan.	Konuma T, Ooi J, Uchida N, Ogawa H, Ohashi K, Kanamori H, Aotsuka N, Onishi Y, Yamaguchi H, Kozai Y, Nagamura-Inoue T, Kato K, Suzuki R, Atsuta Y, Kato S, Asano S, Takahashi S.	Haematologica	2014	99(12):e264-8.	U18
19	Mycophenolate mofetil use after unrelated hematopoietic stem cell transplantation for prophylaxis and treatment of graft-vs.-host disease in adult patients in Japan.	Iida M, Fukuda T, Uchida N, Murata M, Aotsuka N, Minagawa K, Oohashi K, Fukushima K, Kondo T, Eto T, Miyamoto T, Morishima Y, Nagamura T, Atsuta Y, Suzuki R.	Clin Transplant	2014	28(9):980-9.	U19

20	Allogeneic transplantation for primary myelofibrosis with BM, peripheral blood or umbilical cord blood: an analysis of the JSHCT.	Murata M, Nishida T, Taniguchi S, Ohashi K, Ogawa H, Fukuda T, Mori T, Kobayashi H, Nakaseko C, Yamagata N, Morishima Y, Nagamura-Inoue T, Sakamaki H, Atsuta Y, Suzuki R, Naoe T.	Bone Marrow Transplant	2014	49(3):355-60.	U20
21	Hematopoietic stem cell transplantation for inborn errors of metabolism: A report from the Research Committee on Transplantation for Inborn Errors of Metabolism of the Japanese Ministry of Health, Labour and Welfare and the Working Group of the Japan Society for Hematopoietic Cell Transplantation.	Kato S, Yabe H, Takakura H, Mugishima H, Ishige M, Tanaka A, Kato K, Yoshida N, Adachi S, Sakai N, Hashii Y, Ohashi T, Sasahara Y, Suzuki Y, Tabuchi K.	Pediatr Transplant	2016	20(2):203-14.	U21
22	A phase I/II trial of intrabone marrow cord blood transplantation and comparison of the hematological recovery with the Japanese nationwide database.	Kurita N, Goshō M, Yokoyama Y, Kato T, Obara N, Sakata-Yanagimoto M, Hasegawa Y, Uchida N, Takahashi S, Kouzai Y, Atsuta Y, Kurata M, Ichinohe T, Chiba S.	Bone Marrow Transplant	2017	52(4):574-9.	U22
23	Comparison of Conditioning with Fludarabine/Busulfan and Fludarabine/Melphalan in Allogeneic Transplantation Recipients 50 Years or Older.	Kawamura K, Kako S, Mizuta S, Ishiyama K, Aoki J, Yano S, Fukuda T, Uchida N, Ozawa Y, Eto T, Iwato K, Kanamori H, Kahata K, Kondo T, Sawa M, Ichinohe T, Atsuta Y, Kanda Y.	Biol Blood Marrow Transplant	2017	23(12):2079-87.	U23
24	Impact of a Low CD34+ Cell Dose on Allogeneic Peripheral Blood Stem Cell Transplantation.	Yamamoto C, Ogawa H, Fukuda T, Igarashi A, Okumura H, Uchida N, Hidaka M, Nakamae H, Matsuoka KI, Eto T, Ichinohe T, Atsuta Y, Kanda Y.	Biol Blood Marrow Transplant	2018	24(4):708-16.	U24
25	Impact of HIV Infection on Transplant Outcomes after Autologous Peripheral Blood Stem Cell Transplantation: A Retrospective Study of Japanese Registry Data.	Yoshinaga N, Kanda J, Aisa Y, Hagiwara S, Mori T, Fukuda T, Ishida Y, Hashimoto H, Iwato K, Kanda Y, Kurokawa M, Nakazawa H, Ota S, Uchida N, Ichinohe T, Atsuta Y, Takaori-Kondo A.	Biol Blood Marrow Transplant	2018	24(8):1596-601.	U25
26	Somatic Mutations and Clonal Hematopoiesis in Aplastic Anemia.	Yoshizato T, Dumitriu B, Hosokawa K, Makishima H, Yoshida K, Townsley D, Sato-Otsubo A, Sato Y, Liu D, Suzuki H, Wu CO, Shiraishi Y, Clemente MJ, Kataoka K, Shiozawa Y, Okuno Y, Chiba K, Tanaka H, Nagata Y, Katagiri T, Kon A, Sanada M, Scheinberg P, Miyano S, Maciejewski JP, Nakao S, Young NS, Ogawa S.	N Engl J Med	2015	373(1):35-47.	U26
27	Safety and Efficacy of Once-Daily Intravenous Busulfan in Allogeneic Transplantation: A Matched-Pair Analysis.	Kako S, Fujiwara S, Sato M, Kimura SI, Nakasone H, Ohashi K, Kawakita T, Maeda T, Morishita T, Suzuki R, Fukuda T, Ichinohe T, Kurata M, Atsuta Y, Kanda Y.	Biol Blood Marrow Transplant	2018	24(10):2139-44.	U27
28	Impact of pretransplant leukemic blast% in bone marrow and peripheral blood on transplantation outcomes of patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation in non-CR.	Ogawa H, Ikegame K, Daimon T, Uchida N, Fukuda T, Kakihana K, Eto T, Ozawa Y, Kanamori H, Hidaka M, Iwato Y, Ichinohe T, Takanashi M, Atsuta Y, Kanda Y.	Bone Marrow Transplant	2018	53(4):478-82.	U28

29	Efficacy and Long-Term Outcomes of Autologous Stem Cell Transplantation in POEMS Syndrome: A Nationwide Survey in Japan.	Kawajiri-Manako C, Sakaida E, Ohwada C, Miyamoto T, Azuma T, Taguchi J, Mori T, Hasegawa Y, Kondo T, Yujiri T, Yoshimitsu M, Imada K, Kurahashi S, Kahata K, Ichinohe T, Hirokawa M, Atsuta Y, Nakaseko C.	Biol Blood Marrow Transplant	2018	24(6):1180-6.	U29
30	日本骨髓バンクドナーの2回骨髓提供に関する検討.	折原勝己, 吾郷浩厚, 奥山美樹, 落合亮一, 澤正史, 田野崎隆二, 玉井佳子, 豊嶋崇徳, 中尾康夫, 日野雅之, 宮崎泰司, 神田善伸, 金森平和.	日本造血細胞移植学会雑誌	2017	6(2):108-14.	U30
31	Successful preemptive donor lymphocyte infusions from a haploidentical donor in a boy with E2A-HLF-positive ALL.	Hirai M, Yagasaki H, Fujimura J, Inoue M, Shimosawa K, Okuma H, Chin M, Takahashi S.	Leuk Lymphoma	2018	59(3):746-8.	U31
32	Prophylaxis and treatment with mycophenolate mofetil in children with graft-versus-host disease undergoing allogeneic hematopoietic stem cell transplantation: a nationwide survey in Japan.	Kawashima N, Iida M, Suzuki R, Fukuda T, Atsuta Y, Hashii Y, Inoue M, Kobayashi M, Yabe H, Okada K, Adachi S, Yuza Y, Kawa K, Kato K.	Int J Hematol	2019	109(4):491-8.	U32
33	High probability of follow-up termination among AYA survivors after allogeneic hematopoietic cell transplantation.	Miyamura K, Yamashita T, Atsuta Y, Ichinohe T, Kato K, Uchida N, Fukuda T, Ohashi K, Ogawa H, Eto T, Inoue M, Takahashi S, Mori T, Kanamori H, Yabe H, Hama A, Okamoto S, Inamoto Y.	Blood Advances	2019	3(3):397-405.	U33
34	A consideration for efficient unrelated hematopoietic stem cell source acquisition—from an experience of Japan.	Nishiwaki S, Miyamura K, Kanda Y, Takahashi M, Uchida N, Fukuda T, Ikegame K, Ohashi K, Eto T, Ozawa Y, Shiratori S, Iwato K, Matsuoka KI, Hidaka M, Ichinohe T, Atsuta Y, Kodera Y, Okamoto S.	Bone Marrow Transplant	2020	55(3):657-60.	U34
35	Retrospective analysis of children with high-risk acute myeloid leukemia who underwent allogeneic hematopoietic stem cell transplantation following complete remission with initial induction chemotherapy in the AML-05 clinical trial.	Hyakuna N, Hashii Y, Ishida H, Umeda K, Takahashi Y, Nagasawa M, Yabe H, Nakazawa Y, Koh K, Goto H, Fujisaki H, Matsumoto K, Kakuda H, Yano M, Tawa A, Tomizawa D, Taga T, Adachi S, Kato K.	Pediatr Blood Cancer	2019	66(10):e27875.	U35
36	Nationwide retrospective review of hematopoietic stem cell transplantation in children with refractory Langerhans cell histiocytosis.	Kudo K, Maeda M, Suzuki N, Kanegane H, Ohga S, Ishii E, Shioda Y, Imamura T, Imashuku S, Tsunematsu Y, Endo M, Shimada A, Koga Y, Hashii Y, Noguchi M, Inoue M, Tabuchi K, Morimoto A; Histiocytosis study group of the Japanese Society of Pediatric Hematology/Oncology.	Int J Hematol	2020	111(1):137-48.	U36
37	A high CD34+ cell dose is associated with better disease-free survival in patients with low-risk diseases undergoing peripheral blood stem cell transplantation from HLA-matched related donors.	Yokoyama Y, Maie K, Fukuda T, Uchida N, Mukae J, Sawa M, Kubo K, Kurokawa M, Nakamae H, Ichinohe T, Atsuta Y, Chiba S.	Bone Marrow Transplant	2020	55(9):1726-35.	U37
38	Donor Heme Oxygenase-1 Promoter Gene Polymorphism Predicts Survival after Unrelated Bone Marrow Transplantation for High-Risk Patients.	Horio T, Morishita E, Mizuno S, Uchino K, Hanamura I, Espinoza JL, Morishima Y, Kodera Y, Onizuka M, Kashiwase K, Fukuda T, Doki N, Miyamura K, Mori T, Nakao S, Takami A.	Cancers	2020	12(2):E424.	U38

39	Could the minimum number of haematopoietic stem cells to obtain engraftment exist in unrelated, single cord blood transplantation?	Yabe H, Tabuchi K, Uchida N, Takahashi S, Onishi Y, Aotsuka N, Sugio Y, Ikegame K, Ichinohe T, Takahashi M, Kato K, Atsuta Y, Kanda Y.	Br J Haematol	2020	189(2):e56-60.	U39
40	Heterogeneous impact of cytomegalovirus reactivation on nonrelapse mortality in hematopoietic stem cell transplantation.	Kaito S, Nakajima Y, Hara K, Toya T, Nishida T, Uchida N, Mukae J, Fukuda T, Ozawa Y, Tanaka M, Ikegame K, Katayama Y, Kuriyama T, Kanda J, Atsuta Y, Ogata M, Taguchi A, Ohashi K.	Blood Advances	2020	4(6):1051-61.	U40
41	Use of unapproved or off-label drugs in Japan for the treatment of graft-versus-host disease and post-transplant viral infection.	Kuwatsuka Y, Atsuta Y, Hirakawa A, Uchida N, Inamoto Y, Najima Y, Ikegame K, Eto T, Ozawa Y, Ichinohe T, Inoue M, Kimura T, Okamoto S, Miyamura K, Fukuda T.	Int J Hematol	2020	112(6):841-50.	U41
42	Allogeneic Hematopoietic Stem Cell Transplantation for Post-essential Thrombocytopenia and Post-polycythemia Vera Myelofibrosis.	Murata M, Suzuki R, Nishida T, Shirane S, Shimazu Y, Minami Y, Mori T, Doki N, Kanda Y, Uchida N, Tanaka M, Ishikawa J, Togitani K, Fukuda T, Ichinohe T, Atsuta Y, Nagamura -Inoue T, Kiyoi H.	Intern Med	2020	59(16):1947-56.	U42
43	Does one model fit all? Predicting non-relapse mortality after allogeneic hematopoietic cell transplantation.	Yanada M, Uchida N, Ichinohe T, Fukuda T, Kanda J, Kanda Y, Atsuta Y, Nakasone H.	Bone Marrow Transplant	2021	56(7):1720-22.	U43
44	Which is more important for the selection of cord blood units for haematopoietic cell transplantation: the number of CD34-positive cells or total nucleated cells?	Nakasone H, Tabuchi K, Uchida N, Ohno Y, Matsushashi Y, Takahashi S, Onishi Y, Onizuka M, Kobayashi H, Fukuda T, Ichinohe T, Takanashi M, Kato K, Atsuta Y, Yabe H, Kanda Y.	Br J Haematol	2019	185(1):166-69.	U44
45	Adding melphalan to fludarabine and a myeloablative dose of busulfan improved survival after allogeneic hematopoietic stem cell transplantation in a propensity score-matched cohort of hematological malignancies.	Shimomura Y, Hara M, Yamamoto H, Uchida N, Kawakita T, Ashida T, Takada T, Ikeda T, Morishige S, Maruyama Y, Wake A, Ichinohe T, Fukuda T, Takanashi M, Atsuta Y, Ishikawa T.	Bone Marrow Transplant		56(7):1691-99.	U45
46	Peritransplant glucocorticoids redistribute donor T cells to the bone marrow and prevent relapse after haploidentical SCT.	Inoue T, Koyama M, Kaida K, Ikegame K, Kathleen S Ensby, Luke Samson, Takahashi S, Ping Zhang, Simone A Minnie, Maruyama S, Ishii S, Daimon T, Fukuda T, Nakamae H, Ara T, Maruyama Y, Ishiyama K, Ichinohe T, Atsuta Y, Bruce R Blazar, Scott N Furlan, Ogawa H, Geoffrey R Hill.	JCI inSIGHT	2021	6(22):e153551.	U46
47	Cord blood index predicts engraftment and early non-relapse mortality in adult patients with single-unit cord blood transplantation.	Kondo G, Ishimaru F, Konuma T, Takahashi S, Atsuta Y, Ogawa A, Minemoto M, Kashiwase K, Azuma F, Ito M, Isoyama K, Kobayashi T, Ohashi K, Nakajima F, Hiruma K, Makino S, Mugishima H, Namba N, Tsuno H, Nagai T, Muroi K, Nakajima K and on behalf of the Japanese Red Cross Kanto-Koshinetsu Cord Blood Bank.	EBMT	2021	56(11):2771-78.	U47

48	Reduced intensity conditioning in allogeneic stem cell transplantation for AML with Down syndrome.	Muramatsu H, Sakaguchi H, Taga T, Tabuchi K, Adachi S, Inoue M, Kitoh T, Suminoe A, Yabe H, Azuma E, Shioda Y, Ogawa A, Kinoshita A, Kigasawa H, Osugi Y, Koike K, Kawa K, Kato K, Atsuta Y, Kudo K.	Pediatr Blood Cancer	2014	61(5):925-7.	WGP 1-1
49	Comparison of a fludarabine and melphalan combination-based reduced toxicity conditioning with myeloablative conditioning by radiation and/or busulfan in acute myeloid leukemia in Japanese children and adolescents.	Ishida H, Adachi S, Hasegawa D, Okamoto Y, Goto H, Inagaki J, Inoue M, Koh K, Yabe H, Kawa K, Kato K, Atsuta Y, Kudo K.	Pediatr Blood Cancer	2015	62(5):883-9.	WGP 1-2
50	Comparison of Outcomes for Pediatric Patients With Acute Myeloid Leukemia in Remission and Undergoing Allogeneic Hematopoietic Cell Transplantation With Myeloablative Conditioning Regimens Based on Either Intravenous Busulfan or Total Body Irradiation: A Report From the Japanese Society for Hematopoietic Cell Transplantation.	Ishida H, Kato M, Kudo K, Taga T, Tomizawa D, Miyamura T, Goto H, Inagaki J, Koh K, Terui K, Ogawa A, Kawano Y, Inoue M, Sawada A, Kato K, Atsuta Y, Yamashita T, Adachi S.	Biol Blood Marrow Transplant	2015	21(12):2141-7.	WGP 1-3
51	Role of Second Transplantation for Children With Acute Myeloid Leukemia Following Posttransplantation Relapse.	Taga T, Murakami Y, Tabuchi K, Adachi S, Tomizawa D, Kojima Y, Kato K, Koike K, Koh K, Kajiwara R, Hamamoto K, Yabe H, Kawa K, Atsuta Y, Kudo K.	Pediatr Blood Cancer	2016	63(4):701-5.	WGP 1-4
52	Allogeneic Hematopoietic Stem Cell Transplantation for Adolescents and Young Adults with Acute Myeloid Leukemia.	Tomizawa D, Tanaka S, Kondo T, Hashii Y, Arai Y, Kudo K, Taga T, Fukuda T, Goto H, Inagaki J, Koh K, Ohashi K, Ozawa Y, Inoue M, Kato K, Tanaka J, Atsuta Y, Adachi S, Ishida H.	Biol Blood Marrow Transplant	2017	23(9):1515-22.	WGP 1-5
53	Allogeneic hematopoietic stem cell transplantation for children and adolescents with high-risk cytogenetic AML: distinctly poor outcomes of FUS-ERG-positive cases.	Tomizawa D, Yoshida M, Kondo T, Miyamura T, Taga T, Adachi S, Koh K, Noguchi M, Kakuda H, Watanabe K, Cho Y, Fukuda T, Kato M, Shiba N, Goto H, Okada K, Inoue M, Hashii Y, Atsuta Y, Ishida H.	Bone Marrow Transplant	2019	54(3):393-401.	WGP 1-6
54	Comparison of conditioning regimens for autologous stem cell transplantation in children with acute myeloid leukemia: A nationwide retrospective study in Japan.	Sakaguchi H, Muramatsu H, Hasegawa D, Kudo K, Ishida H, Yoshida N, Koh K, Noguchi M, Shiba N, Tokimasa S, Fukuda T, Goto H, Miyamura T, Nakazawa Y, Hashii Y, Inoue M, Atsuta Y; Pediatric AML Working Group of the Japan Society for Hematopoietic Cell Transplantation.	Pediatr Blood Cancer	2019	66(1):e27459.	WGP 1-7
55	Hematopoietic stem-cell transplantation in children with refractory acute myeloid leukemia.	Okamoto Y, Kudo K, Tabuchi K, Tomizawa D, Taga T, Goto H, Yabe H, Nakazawa Y, Koh K, Ikegame K, Yoshida N, Uchida N, Watanabe K, Koga Y, Inoue M, Kato K, Atsuta Y, Ishida H.	Bone Marrow Transplant	2019	54(9):1489-98.	WGP 1-8
56	Hematopoietic stem cell transplantation for pediatric acute myeloid leukemia patients with KMT2A rearrangement: A nationwide retrospective analysis in Japan.	Miyamura T, Kudo K, Tabuchi K, Ishida H, Tomizawa D, Adachi S, Goto H, Yoshida N, Inoue M, Koh K, Sasahara Y, Fujita N, Kakuda H, Noguchi M, Hiwatari M, Hashii Y, Kato K, Atsuta Y, Okamoto Y.	Leuk Res	2019	87:106263.	WGP 1-9
57	Hematopoietic stem cell transplantation for pediatric acute promyelocytic leukemia in Japan.	Yamamoto S, Tomizawa D, Kudo K, Hasegawa D, Taga T, Yanada M, Kondo T, Nakazawa Y, Eto T, Inoue M, Kato K, Atsuta Y, Ishida H.	Pediatr Blood Cancer	2020	67(5):e28181.	WGP 1-10
58	Effect of extramedullary disease on allogeneic hematopoietic cell transplantation for pediatric acute myeloid leukemia: a nationwide retrospective study.	Sakaguchi H, Miyamura T, Tomizawa D, Taga T, Ishida H, Okamoto Y, Koh K, Yokosuka T, Yoshida N, Sato M, Noguchi M, Okada K, Hori T, Takeuchi M, Kosaka Y, Inoue M, Hashii Y, Atsuta Y.	Bone Marrow Transplant	2021	56(8):1859-65.	WGP 1-11

59	Donor lymphocyte infusion for the treatment of relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation: a retrospective analysis by the Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation.	Takami A, Yano S, Yokoyama H, Kuwatsuka Y, Yamaguchi T, Kanda Y, Morishima Y, Fukuda T, Miyazaki Y, Nakamae H, Tanaka J, Atsuta Y, Kanamori H.	Biol Blood Marrow Transplant	2014	20(11):1785-90.	WGP 2-1
60	Outcome of allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia patients with central nervous system involvement.	Aoki J, Ishiyama K, Taniguchi S, Fukuda T, Ohashi K, Ogawa H, Kanamori H, Eto T, Iwato K, Sakamaki H, Morishima Y, Nagamura T, Atsuta Y, Takami A.	Biol Blood Marrow Transplant	2014	20(12):2029-33.	WGP 2-2
61	Efficiency of high-dose cytarabine added to CY/TBI in cord blood transplantation for myeloid malignancy.	Arai Y, Takeda J, Aoki K, Kondo T, Takahashi S, Onishi Y, Ozawa Y, Aotsuka N, Kouzai Y, Nakamae H, Ota S, Nakaseko C, Yamaguchi H, Kato K, Atsuta Y, Takami A ; AML and MDS Working Group of the Japan Society for Hematopoietic Cell Transplantation.	Blood	2015	126(3):415-22.	WGP 2-3
62	Clinical significance of high-dose cytarabine added to cyclophosphamide/total-body irradiation in bone marrow or peripheral blood stem cell transplantation for myeloid malignancy.	Arai Y, Aoki K, Takeda J, Kondo T, Eto T, Ota S, Hashimoto H, Fukuda T, Ozawa Y, Kanda Y, Kato C, Kurokawa M, Iwato K, Onizuka M, Ichinohe T, Atsuta Y, Takami A ; AML and MDS Working Group of Japan Society for Hematopoietic Cell Transplantation.	J Hematol Oncol	2015	8:102.	WGP 2-4
63	Impact of age on outcomes of allogeneic hematopoietic stem cell transplantation with reduced intensity conditioning in elderly patients with acute myeloid leukemia.	Aoki J, Kanamori H, Tanaka M, Yamasaki S, Fukuda T, Ogawa H, Iwato K, Ohashi K, Okumura H, Onizuka M, Maesako Y, Teshima T, Kobayashi N, Morishima Y, Hirokawa M, Atsuta Y, Yano S, Takami A.	Am J Hematol	2016	91(3):302-7.	WGP 2-5
64	Impact of low-dose TBI on outcomes of reduced intensity conditioning allogeneic hematopoietic stem cell transplantation for AML.	Aoki J, Seo S, Kanamori H, Tanaka M, Fukuda T, Onizuka M, Kobayashi N, Kondo T, Sawa M, Uchida N, Iwato K, Ichinohe T, Atsuta Y, Yano S, Takami A.	Bone Marrow Transplant	2016	51(4):604-6.	WGP 2-6
65	Comparable outcomes between autologous and allogeneic transplant for adult acute myeloid leukemia in first CR.	Mizutani M, Hara M, Fujita H, Aoki J, Kanamori H, Ohashi K, Usuki K, Fukuda T, Chou T, Tanaka J, Atsuta Y, Takami A.	Bone Marrow Transplant	2016	51(5):645-53.	WGP 2-7
66	Outcomes of allogeneic hematopoietic cell transplantation in patients with biphenotypic acute leukemia.	Mori J, Ishiyama K, Yamaguchi T, Tanaka J, Uchida N, Kobayashi T, Fukuda T, Kanamori H, Miyamura K, Takahashi S, Eto T, Hirokawa M, Mori S, Nagamura T, Atsuta Y, Takami A.	Ann Hematol	2016	95(2):295-300.	WGP 2-8
67	Acute megakaryoblastic leukemia, unlike acute erythroid leukemia, predicts an unfavorable outcome after allogeneic HSCT.	Ishiyama K, Yamaguchi T, Eto T, Ohashi K, Uchida N, Kanamori H, Fukuda T, Miyamura K, Inoue Y, Taguchi J, Mori T, Iwato K, Morishima Y, Nagamura-Inoue T, Atsuta Y, Sakamaki H, Takami A.	Leuk Res	2016	47:47-53.	WGP 2-9
68	Role of reduced-intensity conditioning allogeneic hematopoietic cell transplantation in older patients with de novo acute myeloid leukemia.	Yamasaki S, Hirakawa A, Aoki J, Uchida N, Fukuda T, Ogawa H, Ohashi K, Kondo T, Eto T, Kanamori H, Okumura H, Iwato K, Ichinohe T, Kanda J, Onizuka M, Kuwatsuka Y, Yanada M, Atsuta Y, Takami A, Yano S.	Ann Hematol	2017	96(2):289-97.	WGP 2-10
69	Reduced-intensity conditioning allogeneic hematopoietic cell transplantation for younger patients with acute myeloid leukemia: a registry-based study.	Yanada M, Kurosawa S, Kobayashi T, Ozawa Y, Kanamori H, Kobayashi N, Sawa M, Nakamae H, Uchida N, Hashimoto H, Fukuda T, Hirokawa M, Atsuta Y, Yano S.	Bone Marrow Transplant	2017	52(6):818-24.	WGP 2-11

70	Allogeneic Hematopoietic Cell Transplantation for Leukemic Transformation Preceded by Philadelphia Chromosome-Negative Myeloproliferative Neoplasms: A Nationwide Survey by the Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation.	Takagi S, Masuoka K, Uchida N, Kurokawa M, Nakamae H, Imada K, Iwato K, Ichinohe T, Atsuta Y, Takami A, Yano S.	Biol Blood Marrow Transplant	2016	22(12):2208-13.	WGP 2-12
71	Outcome of allogeneic hematopoietic stem cell transplantation in adult patients with acute myeloid leukemia harboring trisomy 8.	Konuma T, Kondo T, Yamashita T, Uchida N, Fukuda T, Ozawa Y, Ohashi K, Ogawa H, Kato C, Takahashi S, Kanamori H, Eto T, Nakaseko C, Kohno A, Ichinohe T, Atsuta Y, Takami A, Yano S; Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation (JSHCT).	Ann Hematol	2017	96(3):469-78.	WGP 2-13
72	Autologous hematopoietic cell transplantation for acute promyelocytic leukemia in second complete remission: outcomes before and after the introduction of arsenic trioxide.	Yanada M, Yano S, Kanamori H, Gotoh M, Emi N, Watakabe K, Kurokawa M, Nishikawa A, Mori T, Tomita N, Murata M, Hashimoto H, Henzan H, Kanda Y, Sawa M, Kohno A, Atsuta Y, Ichinohe T, Takami A.	Leuk Lymphoma	2017	58(5):1061-7.	WGP 2-14
73	Outcomes of Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Patients with Abnormalities of the Short Arm of Chromosome 17.	Mori J, Yanada M, Uchida N, Fukuda T, Sakura T, Hidaka M, Watakabe-Inamoto K, Kanamori H, Ogawa H, Ichinohe T, Tanaka J, Atsuta Y, Yano S.	Biol Blood Marrow Transplant	2017	23(8):1398-404.	WGP 2-15
74	Effect of cytogenetic risk status on outcomes for patients with acute myeloid leukemia undergoing various types of allogeneic hematopoietic cell transplantation: an analysis of 7812 patients.	Yanada M, Mori J, Aoki J, Harada K, Mizuno S, Uchida N, Kurosawa S, Toya T, Kanamori H, Ozawa Y, Ogawa H, Henzan H, Iwato K, Sakura T, Ota S, Fukuda T, Ichinohe T, Atsuta Y, Yano S.	Leuk Lymphoma	2018	59(3):601-9.	WGP 2-16
75	Outcomes after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia harboring t(7;11)(p15;p15).	Harada K, Doki N, Aoki J, Mori J, Machida S, Masuko M, Uchida N, Najima Y, Fukuda T, Kanamori H, Ogawa H, Ota S, Ogawa K, Takahashi S, Kasai M, Maeda A, Nagafuji K, Kawakita T, Ichinohe T, Atsuta Y.	Haematologica	2018	103(2):e69-72.	WGP 2-17
76	Comparison of Autologous and Unrelated Transplants for Cytogenetically Normal Acute Myelogenous Leukemia.	Mizutani M, Takami A, Hara M, Mizuno S, Yanada M, Chou T, Uchiyama H, Ohashi K, Miyamoto T, Ozawa Y, Imataki O, Kobayashi N, Uchida N, Kanamori H, Kamimura T, Eto T, Onizuka M, Tanaka J, Atsuta Y, Yano S.	Biol Blood Marrow Transplant	2017	23(9):1447-54.	WGP 2-18
77	Allogeneic haematopoietic cell transplantation for adult acute myeloid leukaemia in second remission: a retrospective study of the Adult Acute Myeloid Leukaemia Working Group of the Japan Society for Haematopoietic Cell Transplantation (JSHCT).	Konuma T, Yanada M, Yamasaki S, Kuwatsuka Y, Fukuda T, Kobayashi T, Ozawa Y, Uchida N, Ota S, Hoshino T, Takahashi S, Kanda Y, Ueda Y, Takanashi M, Kanda J, Ichinohe T, Atsuta Y, Yano S.	Br J Haematol	2018	182(2):245-50.	WGP 2-19
78	Allogeneic hematopoietic cell transplantation in adult acute myeloid leukemia with 11q23 abnormality: a retrospective study of the Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation (JSHCT).	Konuma T, Mizuno S, Kondo T, Yamaguchi H, Fukuda T, Uchida N, Najima Y, Kanamori H, Ota S, Nakamae H, Nakamae M, Mizuno I, Sugita J, Onishi Y, Yokota A, Takahashi S, Kanda Y, Ichinohe T, Atsuta Y, Yano S; Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation (JSHCT).	Ann Hematol	2018	97(11):2173-83.	WGP 2-20
79	Patients with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation: trends in survival during the past two decades.	Yanada M, Masuko M, Mori J, Aoki J, Mizuno S, Fukuda T, Kakihana K, Ozawa Y, Ota S, Kanamori H, Mori T, Nakamae H, Eto T, Shiratori S, Maeda T, Iwato K, Ichinohe T, Kanda Y, Tanaka J, Atsuta Y, Yano S.	Bone Marrow Transplant	2019	54(4):578-86.	WGP 2-21

80	Prognostic impact of melphalan dose and total body irradiation use in patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation with reduced-intensity conditioning.	Harada K, Yanada M, Machida S, Kanamori H, Onizuka M, Ozawa Y, Kobayashi H, Sawa M, Katayama Y, Ohashi K, Kanda J, Ichinohe T, Atsuta Y, Yano S.	Leuk Lymphoma	2019	60(6):1493-502.	WGP 2-22
81	Hematopoietic Cell Transplantation for Acute Panmyelosis with Myelofibrosis: A Retrospective Study in Japan.	Konuma T, Kondo T, Kawata T, Iwato K3, Sato Y, Mori T, Ohashi K, Nakazawa H, Sugahara H, Ago H, Eto T, Imamura Y, Fukuda T, Kanda Y, Atsuta Y, Yano S; Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation.	Biol Blood Marrow Transplant	2019	25(1):e23-7.	WGP 2-23
82	Upfront allogeneic hematopoietic cell transplantation (HCT) versus remission induction chemotherapy followed by allogeneic HCT for acute myeloid leukemia with multilineage dysplasia: A propensity score matched analysis.	Konuma T, Harada K, Yamasaki S, Mizuno S, Uchida N, Takahashi S, Onizuka M, Nakamae H, Hidaka M, Fukuda T, Ohashi K, Kohno A, Matsushita A, Kanamori H, Ashida T, Kanda J, Atsuta Y, Yano S; Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation.	Am J Hematol	2019	94(1):103-10.	WGP 2-24
83	Effect of allogeneic stem cell transplantation in patients with minimally differentiated acute myeloid leukemia.	Yamasaki S, Aoki J, Mori J, Harada K, Sawa M, Uchida M, Ohashi K, Fukuda T, Koh S, Kanamori H, Ogawa H, Okumura H, Ichinohe T, Kanda Y, Tanaka J, Atsuta Y, Yanada M, Yano S.	日本造血細胞移植学会雑誌	2019	8(2):50-9.	WGP 2-25
84	Unit selection for umbilical cord blood transplantation for adults with acute myeloid leukemia in complete remission: a Japanese experience.	Yanada M, Konuma T, Kuwatsuka Y, Kondo T, Kawata T, Takahashi S, Uchida N, Miyakoshi S, Tanaka M, Ozawa Y, Sawa M, Nakamae H, Aotsuka N, Kanda, Takanashi M, Kanda Y, Atsuta Y, Yano S.	Bone Marrow Transplant	2019	54(11):1789-98.	WGP 2-26
85	Risk stratification and prognosticators of acute myeloid leukemia with myelodysplasia-related changes patients undergoing allogeneic stem cell transplantation: a retrospective study of the Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation.	Harada K, Konuma T, Machida S, Mori J, Aoki J, Uchida N, Ohashi K, Fukuda T, Tanaka M, Ikegame K, Ozawa Y, Iwato K, Eto T, Onizuka M, Ichinohe T, Atsuta Y, Yano S.	Biol Blood Marrow Transplant	2019	25(9):1730-43.	WGP 2-27
86	Role of alternative donor allogeneic hematopoietic stem cell transplantation in patients with intermediate- or poor-risk acute myeloid leukemia in first complete remission.	Yano S, Yokoyama H, Yanada M, Mori J, Aoki J, Ohashi K, Kanomori H, Ozawa Y, Sawa M, Nakamae H, Eto T, Ohta S, Tanaka J, Ichinohe T, Atsuta Y, Takami A.	Bone Marrow Transplant	2019	54(12):2004-12.	WGP 2-28
87	Better disease control before allogeneic stem cell transplantation is crucial to improve the outcomes of transplantation for acute myeloid leukemia patients with extramedullary disease.	Yamasaki S, Aoki J, Mori J, Mizuno S, Uchida N, Ohashi K, Fukuda T, Ikegame K, Eto T, Ogawa Y, Tanaka M, Hidaka M, Iwato K, Sawa M, Ichinohe T, Kanda Y, Atsuta Y, Yanada M, Yano S; Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation.	Bone Marrow Transplant	2020	55(1):249-52.	WGP 2-29
88	Time-Varying Effects of Graft Type on Outcomes for Patients with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation.	Yanada M, Konuma T, Yamasaki S, Kuwatsuka Y, Masuko M, Tanaka M, Ozawa Y, Toya T, Fukuda T, Ota S, Sawa M, Uchida N, Nakamae H, Eto T, Kanda J, Takanashi M, Kanda Y, Atsuta Y, Yano S.	Biol Blood Marrow Transplant	2020	26(2):307-15.	WGP 2-30
89	Allogeneic hematopoietic cell transplantation for patients with a history of multiple relapses of acute myeloid leukemia.	Yanada M, Mori J, Aoki J, Masuko M, Harada K, Uchida N, Doki N, Fukuda T, Sakura T, Kanamori H, Sawa M, Kondo T, Katayama Y, Kanda J, Ichinohe T, Atsuta Y, Yano S.	Ann Hematol	2019	98(9):2179-86.	WGP 2-31
90	Autologous hematopoietic cell transplantation for acute myeloid leukemia in adults: 25 years of experience in Japan.	Yanada M, Takami A, Mizuno S, Mori J, Chou T, Usuki K, Uchiyama H, Amano I, Fujii S, Miyamoto T, Saito T, Kamimura T, Ichinohe T, Fukuda T, Okamoto S, Atsuta Y, Yano S.	Int J Hematol	2020	111(1):93-102.	WGP 2-32

91	Conditioning Intensity for Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Patients with Poor-Prognosis Cytogenetics in First Complete Remission.	Konuma T, Kondo T, Mizuno S, Doki N, Aoki J, Fukuda T, Tanaka M, Sawa M, Katayama Y, Uchida N, Ozawa Y, Morishige S, Matsuoka KI, Ichinohe T, Onizuka M, Kanda J, Atsuta Y, Yanada M; Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation.	Biol Blood Marrow Transplant	2020	26(3):463-71.	WGP 2-33
92	Long-term results of reduced-intensity conditioning allogeneic hematopoietic cell transplantation for older patients with acute myeloid leukemia: a retrospective analysis of 10-year follow-up data.	Yanada M, Fukuda T, Tanaka M, Ota S, Toya T, Mori T, Uchida N, Ozawa Y, Nakamae H, Kanda Y, Ichinohe T, Atsuta Y, Yano S.	Bone Marrow Transplant	2020	55(10):2008-16.	WGP 2-34
93	Allogeneic hematopoietic cell transplantation for adults with acute myeloid leukemia conducted in Japan during the past quarter century.	Yanada M, Takami A, Yamasaki S, Arai Y, Konuma T, Uchida N, Najima Y, Fukuda T, Tanaka M, Ozawa Y, Ikegame K, Takanashi M, Ichinohe T, Okamoto S, Atsuta Y, Yano S.	Ann Hematol	2020	99(6):1351-60.	WGP 2-35
94	Allogeneic hematopoietic cell transplantation efficacy in patients with Philadelphia chromosome-positive acute myeloid leukemia in complete remission.	Mizuno S, Yanada M, Kawamura K, Masuko M, Uchida N, Ozawa Y, Iwato K, Ohashi K, Ikegame K, Kim SW, Tanaka M, Eto T, Kanda Y, Fukuda T, Atsuta Y, Yano S, Takami A.	Bone Marrow Transplant	2021	56(1):232-42.	WGP 2-36
95	Predicting non-relapse mortality following allogeneic hematopoietic cell transplantation during first remission of acute myeloid leukemia.	Yanada M, Konuma T, Mizuno S, Saburi M, Shinohara A, Tanaka M, Marumo A, Sawa M, Uchida N, Ozawa Y, Onizuka M, Yoshioka S, Nakamae H, Kondo T, Kimura T, Kanda J, Fukuda T, Atsuta Y, Nakasone H, Yano S.	Bone Marrow Transplant	2021	56(2):387-94.	WGP 2-37
96	Effect of allogeneic HCT from unrelated donors in AML patients with intermediate- or poor-risk cytogenetics: a retrospective study from the Japanese Society for HCT.	Yamasaki S, Mori J, Kanda J, Imahashi N, Uchida N, Doki N, Tanaka M, Katayama Y, Eto T, Ozawa Y, Takada S, Onizuka M, Hino M, Kanda Y, Fukuda T, Atsuta Y, Yanada M.	Ann Hematol	2020	99(12):2927-37.	WGP 2-38
97	Relapse of acute myeloid leukemia after allogeneic hematopoietic cell transplantation: clinical features and outcomes.	Yanada M, Konuma T, Yamasaki S, Kondo T, Fukuda T, Shingai N, Sawa M, Ozawa Y, Tanaka M, Uchida N, Nakamae H, Katayama Y, Matsuoka KI, Kimura T, Kanda Y, Ichinohe T, Atsuta Y, Yano S.	Bone Marrow Transplant	2021	56(5):1126-33.	WGP 2-39
98	Prognostic Impact of the Fractionation of Total Body Irradiation for Patients with Acute Myeloid Leukemia Undergoing Myeloablative Allogeneic Hematopoietic Cell Transplantation.	Ueda N, Konuma T, Aoki J, Takahashi S, Ozawa Y, Mori T, Ota S, Eto T, Takada S, Yoshioka S, Shiratori S, Kako S, Onizuka M, Fukuda T, Kanda Y, Atsuta Y, Yanada M.	Transplant Cell Ther	2021	27(2):185.e1-6.	WGP 2-40
99	Single Cord Blood Transplantation Versus Unmanipulated Haploidentical Transplantation for Adults with Acute Myeloid Leukemia in Complete Remission.	Konuma T, Kanda J, Yamasaki S, Harada K, Shimomura Y, Terakura S, Mizuno S, Uchida N, Tanaka M, Doki N, Ozawa Y, Nakamae H, Sawa M, Matsuoka KI, Morishige S, Maruyama Y, Ikegame K, Kimura T, Kanda Y, Ichinohe T, Atsuta Y, Yanada M.	Transplant Cell Ther	2021	27(4):334.e1-11.	WGP 2-41
100	Allogeneic Hematopoietic Cell Transplantation for Adolescent and Young Adult Patients with Acute Myeloid Leukemia.	Mizuno S, Takami A, Kawamura K, Arai Y, Kondo T, Kawata T, Uchida N, Marumo A, Fukuda T, Tanaka M, Ozawa Y, Yoshida S, Ota S, Takada S, Sawa M, Onizuka M, Kanda Y, Ichinohe T, Atsuta Y, Yanada M.	Transplant Cell Ther	2021	27(4):314.e1-10.	WGP 2-42
101	Single cord blood transplantation for acute myeloid leukemia patients aged 60 years or older: a retrospective study in Japan.	Isobe M, Konuma T, Masuko M, Uchida N, Miyakoshi S, Sugio Y, Yoshida S, Tanaka M, Matsuhashi Y, Hattori N, Onizuka M, Aotsuka N, Kouzai Y, Wake A, Kimura T, Ichinohe T, Atsuta Y, Yanada M; Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation.	Ann Hematol	2021	100(7):1849-61.	WGP 2-43

102	Reduced-intensity stem cell transplantation for acute myeloid leukemia with fludarabine-based conditioning with intravenous busulfan versus melphalan.	Yamashita T, Takami A, Uchida N, Fukuda T, Eto T, Shiratori S, Ota S, Akasaka T, Miyakoshi S, Kondo T, Hidaka M, Kanda J, Atsuta Y, Yano S.	Bone Marrow Transplant	2020	55(10):1955-65.	WGP 2-44
103	Personalized prediction of overall survival in patients with AML in non-complete remission undergoing allo-HCT.	Hirabayashi S, Uozumi R, Kondo T, Arai Y, Kawata T, Uchida N, Marumo A, Ikegame K, Fukuda T, Eto T, Tanaka M, Wake A, Kanda J, Kimura T, Tabuchi K, Ichinohe T, Atsuta Y, Yanada M, Yano S.	Cancer Med	2021	10(13):4250-68.	WGP 2-45
104	Difference in outcomes following allogeneic hematopoietic cell transplantation for patients with acute myeloid leukemia and myelodysplastic syndromes.	Yanada M, Mizuno S, Yamasaki S, Harada K, Konuma T, Tamaki H, Shingai N, Uchida N, Ozawa Y, Tanaka M, Onizuka M, Sawa M, Nakamae H, Shiratori S, Matsuoka KI, Eto T, Kawakita T, Maruyama Y, Ichinohe T, Kanda Y, Atsuta Y, Aoki J, Yano S.	Leuk Lymphoma	2021	62(14):3411-9.	WGP 2-46
105	The differential effect of disease status at allogeneic hematopoietic cell transplantation on outcomes in acute myeloid and lymphoblastic leukemia.	Yanada M, Konuma T, Yamasaki S, Mizuno S, Hirabayashi S, Nishiwaki S, Uchida N, Doki N, Tanaka M, Ozawa Y, Sawa M, Eto T, Kawakita T, Ota S, Fukuda T, Onizuka M, Kimura T, Atsuta Y, Kako S, Yano S.	Ann Hematol	2021	100(12):3017-27.	WGP 2-47
106	Syngeneic hematopoietic stem cell transplantation for acute myeloid leukemia: a propensity score-matched analysis.	Kurosawa S, Mizuno S, Arai Y, Masuko M, Kanda J, Kohno K, Onai D, Fukuda T, Ozawa Y, Katayama Y, Tanaka M, Ikegame K, Uchida N, Eto T, Ota S, Tanaka J, Ichinohe T, Atsuta Y, Yanada M.	Blood Cancer J	2021	11(9):159.	WGP 2-48
107	Allogeneic Hematopoietic Cell Transplantation from Alternative Donors in Acute Myelogenous Leukemia: A Comparative Analysis.	Yanada M, Konuma T, Yamasaki S, Harada K, Iwasaki M, Kobayashi A, Nishijima A, Tanaka M, Uchida N, Nakamae H, Fukuda T, Onizuka M, Ozawa Y, Sawa M, Katayama Y, Yoshioka S, Kimura T, Ichinohe T, Atsuta Y, Kanda J, Yano S.	Transplant Cell Ther	2021	27(12):1005.e1-8.	WGP 2-49
108	Autologous hematopoietic cell transplantation during second or subsequent complete remission of acute promyelocytic leukemia: a prognostic factor analysis.	Yanada M, Ota S, Mukae J, Nara M, Kako S, Nishikawa A, Uchida N, Sawa M, Nakano N, Onizuka M, Kanda Y, Ichinohe T, Atsuta Y, Yano S.	Bone Marrow Transplant	2022	57(1):78-82.	WGP 2-50
109	Donor lymphocyte infusion after haploidentical hematopoietic stem cell transplantation for acute myeloid leukemia.	Harada K, Mizuno S, Yano S, Takami A, Ishii H, Ikegame K, Najima Y, Kako S, Ashida T, Shiratori S, Ota S, Onizuka M, Fukushima K, Fukuda T, Ichinohe T, Atsuta Y, Yanada M.	Ann Hematol	2022	101(3):643-53.	WGP 2-51
110	Prognostic value of measurable residual disease at allogeneic transplantation for adults with core binding factor acute myeloid leukemia in complete remission.	Konuma T, Kondo T, Masuko M, Shimizu H, Shiratori S, Fukuda T, Kato J, Sawa M, Ozawa Y, Ota S, Uchida N, Kanda Y, Kako S, Fujisawa S, Fukushima K, Ichinohe T, Atsuta Y, Yanada M; Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation.	Bone Marrow Transplant	2021	56(11):2779-87.	WGP 2-52
111	Comparison of fludarabine, a myeloablative dose of busulfan, and melphalan vs conventional myeloablative conditioning regimen in patients with relapse and refractory acute myeloid leukemia in non-remission status.	Shimomura Y, Hara M, Hirabayashi S, Kondo T, Mizuno S, Uchida N, Mukae J, Kawakita T, Fukuda T, Kanda Y, Ota S, Ozawa Y, Eto T, Maruyama Y, Tanaka M, Nakano N, Kimura T, Ichinohe T, Atsuta Y, Yanada M.	Bone Marrow Transplant	2021	56(9):2302-4.	WGP 2-53
112	Comparing cord blood transplantation and matched related donor transplantation in non-remission acute myeloid leukemia.	Shimomura Y, Sobue T, Hirabayashi S, Kondo T, Mizuno S, Kanda J, Fujino T, Kataoka K, Uchida N, Eto T, Miyakoshi S, Tanaka M, Kawakita T, Yokoyama H, Doki N, Harada K, Wake A, Ota S, Takada S, Takahashi S, Kimura T, Onizuka M, Fukuda T, Atsuta Y, Yanada M.	Leukemia		in press	WGP 2-54

113	Second allogeneic hematopoietic SCT for relapsed ALL in children.	Kato M, Horikoshi Y, Okamoto Y, Takahashi Y, Hasegawa D, Koh K, Takita J, Inoue M, Kigasawa H, Ogawa A, Sasahara Y, Kawa K, Yabe H, Sakamaki H, Suzuki R, Kato K.	Bone Marrow Transplant	2012	47(10):1307-11.	WGP 3-1
114	Comparison of intravenous with oral busulfan in allogeneic hematopoietic stem cell transplantation with myeloablative conditioning regimens for pediatric acute leukemia.	Kato M, Takahashi Y, Tomizawa D, Okamoto Y, Inagaki J, Koh K, Ogawa A, Okada K, Cho Y, Takita J, Goto H, Sakamaki H, Yabe H, Kawa K, Suzuki R, Kudo K, Kato K.	Biol Blood Marrow Transplant	2013	19(12):1690-4.	WGP 3-2
115	Comparison of transplantation with reduced and myeloablative conditioning for children with acute lymphoblastic leukemia.	Kato K, Kato M, Hasegawa D, Kawasaki H, Ishida H, Okamoto Y, Koh K, Inoue M, Inagaki J, Kato K, Sakamaki H, Yabe H, Kawa K, Suzuki R, Atsuta Y.	Blood	2015	125(8):1352-4.	WGP 3-3
116	Hematopoietic stem cell transplantation for patients with acute lymphoblastic leukemia and Down syndrome.	Goto H, Kaneko T, Shioda Y, Kajiwara M, Sakashita K, Kitoh T, Hayakawa A, Miki M, Kato K, Ogawa A, Hashii Y, Inukai T, Kato C, Sakamaki H, Yabe H, Suzuki R, Kato K.	Pediatr Blood Cancer	2015	62(1):148-52.	WGP 3-4
117	Allogeneic haematopoietic stem cell transplantation for infant acute lymphoblastic leukaemia with KMT2A (MLL) rearrangements: a retrospective study from the paediatric acute lymphoblastic leukaemia working group of the Japan Society for Haematopoietic Cell Transplantation.	Kato M, Hasegawa D, Koh K, Kato K, Takita J, Inagaki J, Yabe H, Goto H, Adachi S, Hayakawa A, Takeshita Y, Sawada A, Atsuta Y, Kato K.	Br J Haematol	2015	168(4):564-70.	WGP 3-5
118	Comparison of chemotherapeutic agents as a myeloablative conditioning with total body irradiation for pediatric acute lymphoblastic leukemia: A study from the pediatric ALL working group of the Japan Society for Hematopoietic Cell Transplantation.	Kato M, Ishida H, Koh K, Inagaki J, Kato K, Goto H, Kaneko T, Cho Y, Hashii Y, Kurosawa H, Takita J, Hamamoto K, Inoue M, Sawada A, Suzuki R, Kato K.	Pediatr Blood Cancer	2015	62(10):1844-50.	WGP 3-6
119	Impact of graft-versus-host disease on relapse and survival after allogeneic stem cell transplantation for pediatric leukemia.	Kato M, Kurata M, Kanda J, Kato K, Tomizawa D, Kudo K, Yoshida N, Watanabe K, Shimada H, Inagaki J, Koh K, Goto H, Kato K, Cho Y, Yuza Y, Ogawa A, Okada K, Inoue M, Hashii Y, Teshima T, Murata M, Atsuta Y.	Bone Marrow Transplant	2019	54(1):68-75.	WGP 3-7
120	Allogeneic Stem Cell Transplantation for Acute Lymphoblastic Leukemia in Adolescents and Young Adults.	Hangai M, Urayama KY, Tanaka J, Kato K, Nishiwaki S, Koh K, Noguchi M, Kato K, Yoshida N, Sato M, Goto H, Yuza Y, Hashii Y, Atsuta Y, Mizuta S, Kato M.	Biol Blood Marrow Transplant	2019	25(8):1597-602.	WGP 3-8
121	Unrelated cord blood transplantation with myeloablative conditioning for pediatric acute lymphoblastic leukemia in remission: prognostic factors.	Kawahara Y, Morimoto A, Inagaki J, Koh K, Noguchi M, Goto H, Yoshida N, Cho Y, Hori T, Hiwatari M, Kato K, Ogawa A, Hashii Y, Inoue M, Kato K, Atsuta Y, Kimura F, Kato M.	Bone Marrow Transplant	2021	56(2):357-67.	WGP 3-9
122	Reduced-intensity allogeneic stem cell transplantation for patients aged 50 years or older with B-cell ALL in remission: a retrospective study by the Adult ALL Working Group of the Japan Society for Hematopoietic Cell Transplantation.	Kanamori H, Mizuta S, Kako S, Kato H, Nishiwaki S, Imai K, Shigematsu A, Nakamae H, Tanaka M, Ikegame K, Yujiri T, Fukuda T, Minagawa K, Eto T, Nagamura-Inoue T, Morishima Y, Suzuki R, Sakamaki H, Tanaka J.	Bone Marrow Transplant	2013	48(12):1513-8.	WGP 4-1
123	Impact of a donor source on adult Philadelphia chromosome-negative acute lymphoblastic leukemia: a retrospective analysis from the Adult Acute Lymphoblastic Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation.	Nishiwaki S, Miyamura K, Ohashi K, Kurokawa M, Taniguchi S, Fukuda T, Ikegame K, Takahashi S, Mori T, Imai K, Iida H, Hidaka M, Sakamaki H, Morishima Y, Kato K, Suzuki R, Tanaka J; Adult Acute Lymphoblastic Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation.	Ann Oncol	2013	24(6):1594-602.	WGP 4-2

124	Reduced-intensity vs myeloablative conditioning allogeneic hematopoietic SCT for patients aged over 45 years with ALL in remission: a study from the Adult ALL Working Group of the Japan Society for Hematopoietic Cell Transplantation (JSHCT).	Tanaka J, Kanamori H, Nishiwaki S, Ohashi K, Taniguchi S, Eto T, Nakamae H, Minagawa K, Miyamura K, Sakamaki H, Morishima Y, Kato K, Suzuki R, Nishimoto N, Oba K, Masauzi N.	Bone Marrow Transplant	2013	48(11):1389-94.	WGP 4-3
125	Analysis of outcomes following autologous stem-cell transplantation in adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia during the first complete remission.	Kato H, Kawase T, Kako S, Mizuta S, Kurokawa M, Mori T, Ohashi K, Iwato K, Miyamura K, Hidaka M, Sakamaki H, Suzuki R, Morishima Y, Tanaka J; Adult Acute Lymphoblastic Leukemia Working Group of Japan Society for Hematopoietic Cell Transplantation (JSHCT).	Haematologica	2014	99(11):e228-30.	WGP 4-4
126	Pretransplant administration of imatinib for allo-HSCT in patients with BCR-ABL-positive acute lymphoblastic leukemia.	Mizuta S, Matsuo K, Nishiwaki S, Imai K, Kanamori H, Ohashi K, Fukuda T, Onishi Y, Miyamura K, Takahashi S, Onizuka M, Atsuta Y, Suzuki R, Morishima Y, Kato K, Sakamaki H, Tanaka J.	Blood	2014	123(15):2325-32.	WGP 4-5
127	Impact of MRD and TKI on allogeneic hematopoietic cell transplantation for Ph+ALL: a study from the adult ALL WG of the JSHCT.	Nishiwaki S, Imai K, Mizuta S, Kanamori H, Ohashi K, Fukuda T, Onishi Y, Takahashi S, Uchida N, Eto T, Nakamae H, Yujiri T, Mori S, Nagamura-Inoue T, Suzuki R, Atsuta Y, Tanaka J.	Bone Marrow Transplant	2016	51(1):43-50.	WGP 4-6
128	Comparison of Cyclophosphamide Combined with Total Body Irradiation, Oral Busulfan, or Intravenous Busulfan for Allogeneic Hematopoietic Cell Transplantation in Adults with Acute Lymphoblastic Leukemia.	Mitsuhashi K, Kako S, Shigematsu A, Atsuta Y, Doki N, Fukuda T, Kanamori H, Onizuka M, Takahashi S, Ozawa Y, Kurokawa M, Inoue Y, Nagamura-Inoue T, Morishima Y, Mizuta S, Tanaka J; Adult Acute Lymphoblastic Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation.	Biol Blood Marrow Transplant	2016	22(12):2194-200.	WGP 4-7
129	High-dose cytarabine added to CY/TBI improves the prognosis of cord blood transplantation for acute lymphoblastic leukemia in adults: a retrospective cohort study.	Arai Y, Kondo T, Shigematsu A, Tanaka J, Takahashi S, Kobayashi T, Uchida N, Onishi Y, Ishikawa J, Kanamori H, Sawa M, Yokota A, Kouzai Y, Takanashi M, Ichinohe T, Atsuta Y, Mizuta S.	Bone Marrow Transplant	2016	51(12):1636-9.	WGP 4-8
130	Increased non-relapse mortality due to high-dose cytarabine plus CY/TBI in BMT/PBSCT for acute lymphoblastic leukaemia in adults.	Arai Y, Kondo T, Shigematsu A, Tanaka J, Ohashi K, Fukuda T, Kawakita T, Mori T, Hoshino T, Onizuka M, Ozawa Y, Yoshida S, Ueda Y, Mizuno I, Atsuta Y, Mizuta S; Japan Society for Haematopoietic Cell Transplantation.	Br J Haematol	2017	178(1):106-11.	WGP 4-9
131	Allogeneic stem cell transplantation for adult patients with acute lymphoblastic leukemia who had central nervous system involvement: a study from the Adult ALL Working Group of the Japan Society for Hematopoietic Cell Transplantation.	Shigematsu A, Kako S, Mitsuhashi K, Iwato K, Uchida N, Kanda Y, Fukuda T, Sawa M, Senoo Y, Ogawa H, Miyamura K, Takada S, Nagamura-Inoue T, Morishima Y, Ichinohe T, Atsuta Y, Mizuta S, Tanaka J.	Int J Hematol	2017	105(6):805-11.	WGP 4-10
132	Improved prognosis with additional medium-dose VP16 to CY/TBI in allogeneic transplantation for high risk ALL in adults.	Arai Y, Kondo T, Shigematsu A, Tanaka J, Ohashi K, Fukuda T, Hidaka M, Kobayashi N, Iwato K, Sakura T, Onizuka M, Ozawa Y, Eto T, Kurokawa M, Kahata K, Uchida N, Atsuta Y, Mizuta S, Kako S.	Am J Hematol	2018	93(1):47-57.	WGP 4-11
133	Additional Cytogenetic Abnormalities with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia on Allogeneic Stem Cell Transplantation in the Tyrosine Kinase Inhibitor Era.	Akahoshi Y, Mizuta S, Shimizu H, Uchida N, Fukuda T, Kanamori H, Onizuka M, Ozawa Y, Ohashi K, Ohta S, Eto T, Tanaka J, Atsuta Y, Kako S; Adult Acute Lymphoblastic Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation.	Biol Blood Marrow Transplant	2018	24(10):2009-16.	WGP 4-12

134	Tyrosine kinase inhibitor prophylaxis after transplant for Philadelphia chromosome-positive acute lymphoblastic leukemia.	Akahoshi Y, Nishiwaki S, Mizuta S, Ohashi K, Uchida N, Tanaka M, Fukuda T, Ozawa Y, Takahashi S, Onizuka M, Shiratori S, Nakamae H, Kanda Y, Ichinohe T, Atsuta Y, Kako S.	Cancer Sci	2019	110(10):3255-66.	WGP 4-13
135	Different impact of BCR-ABL transcripts on allogeneic hematopoietic cell transplantation from different graft sources for Ph+ALL with minimal residual disease.	Nishiwaki S, Mizuta S, Ohashi K, Fukuda T, Uchida N, Tachibana T, Onizuka M, Ozawa Y, Onishi Y, Takahashi S, Eto T, Nakamae H, Tanaka J, Ichinohe T, Atsuta Y, Kako S; Adult Acute Lymphoblastic Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation.	Am J Hematol	2019	94(11):E301-5.	WGP 4-14
136	The effect of melphalan dose and total body irradiation as reduced-intensity conditioning for acute lymphoblastic leukemia patients undergoing allogeneic stem cell transplantation.	Harada K, Tachibana T, Ohashi K, Ozawa Y, Sawa M, Kondo T, Ishikawa J, Onizuka M, Imada K, Fujisaki T, Tanaka J, Fukuda T, Atsuta Y, Kako S.	Leuk Lymphoma	2019	60(14):3521-8.	WGP 4-15
137	Allogeneic hematopoietic stem cell transplantation for adult patients with B-cell acute lymphoblastic leukemia harboring t(1;19)(q23;p13.3); comparison with normal karyotype.	Kaito S, Najima Y, Harada K, Fukuda T, Noguchi Y, Ikegame K, Tanaka M, Ozawa Y, Yoshida S, Sawa M, Ota S, Inoue Y, Tanaka J, Ichinohe T, Atsuta Y, Kako S; Adult Acute Lymphoblastic Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation.	Bone Marrow Transplant	2020	55(7):1337-46.	WGP 4-16
138	Impact of graft-versus-host disease and graft-versus-leukemia effect based on minimal residual disease in Philadelphia chromosome-positive acute lymphoblastic leukemia.	Akahoshi Y, Igarashi A, Fukuda T, Uchida N, Tanaka M, Ozawa Y, Kanda Y, Onizuka M, Ichinohe T, Tanaka J, Atsuta Y, Kako S; Adult Acute Lymphoblastic Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation.	Br J Haematol	2020	190(1):84-92.	WGP 4-17
139	Reduced-intensity Conditioning Is a Reasonable Alternative for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Among Elderly Patients Who Have Achieved Negative Minimal Residual Disease: A Report From the Adult Acute Lymphoblastic Leukemia Working Group of the JSHCT.	Akahoshi Y, Nishiwaki S, Arai Y, Harada K, Najima Y, Kanda Y, Shono K, Ota S, Fukuda T, Uchida N, Shiratori S, Tanaka M, Tanaka J, Atsuta Y, Kako S.	Bone Marrow Transplant	2020	55(7):1317-25.	WGP 4-18
140	The impacts of BCR-ABL1 mutations in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia who underwent allogeneic hematopoietic cell transplantation.	Tachibana T, Najima Y, Akahoshi Y, Hirabayashi S, Harada K, Doki N, Uchida N, Fukuda T, Sawa M, Ogata M, Takada S, Tanaka M, Matsuhashi Y, Tanaka J, Onizuka M, Ichinohe T, Atsuta Y, Kako S; Adult ALL Working Group of the Japan Society for Hematopoietic Cell Transplantation.	Ann Hematol	2020	99(10):2393-404.	WGP 4-19
141	Measurable residual disease affects allogeneic hematopoietic cell transplantation in Ph+ ALL during both CR1 and CR2.	Nishiwaki S, Akahoshi Y, Mizuta S, Shinohara A, Hirabayashi S, Noguchi Y, Fukuda T, Uchida N, Tanaka M, Onizuka M, Ozawa Y, Ota S, Shiratori S, Onishi Y, Kanda Y, Sawa M, Tanaka J, Atsuta Y, Kako S.	Blood Advances	2021	5(2):584-92.	WGP 4-20
142	Minimal residual disease (MRD) positivity at allogeneic hematopoietic cell transplantation, not the quantity of MRD, is a risk factor for relapse of Philadelphia chromosome-positive acute lymphoblastic leukemia.	Akahoshi Y, Arai Y, Nishiwaki S, Mizuta S, Marumo A, Uchida N, Kanda Y, Sakai H, Takada S, Fukuda T, Fujisawa S, Ashida T, Tanaka J, Atsuta Y, Kako S.	Int J Hematol	2021	113(6):832-9.	WGP 4-21
143	Allogeneic hematopoietic stem cell transplantation for adult patients with B-cell acute lymphoblastic leukemia with high hyperdiploidy: a retrospective nationwide study.	Kurosawa S, Kaito S, Uchida N, Fukuda T, Doki N, Mori T, Hasegawa Y, Takada S, Sakaida E, Tanaka M, Ikegame K, Kanda J, Atsuta Y, Kako S.	Leuk Lymphoma	2021	62(10):2514-20.	WGP 4-22

144	Residual disease is a strong prognostic marker in patients with acute lymphoblastic leukaemia with chemotherapy-refractory or relapsed disease prior to allogeneic stem cell transplantation.	Nakamura M, Arai Y, Hirabayashi S, Kondo T, Doki N, Uchida N, Fukuda T, Ozawa Y, Tanaka M, Sawa M, Katayama Y, Kanda Y, Shiratori S, Nakamae H, Yoshioka S, Onizuka M, Ichinohe T, Atsuta Y, Kako S.	Br J Haematol	2021	194(2):403-13.	WGP 4-23
145	Newly proposed threshold and validation of white blood cell count at diagnosis for Philadelphia chromosome-positive acute lymphoblastic leukemia: risk assessment of relapse in patients with negative minimal residual disease at transplantation—a report from the Adult Acute Lymphoblastic Leukemia Working Group of the JSTCT.	Akahoshi Y, Arai Y, Nishiwaki S, Tachibana T, Shinohara A, Doki N, Uchida N, Tanaka M, Kanda Y, Shiratori S, Ozawa Y, Shono K, Katayama Y, Tanaka J, Fukuda T, Atsuta Y, Kako S.	Bone Marrow Transplant	2021	56(11):2842-8.	WGP 4-24
146	Optimal treatment for Philadelphia-negative acute lymphoblastic leukemia in first remission in the era of high-intensity chemotherapy.	Kako S, Hayakawa F, Imai K, Tanaka J, Mizuta S, Nishiwaki S, Kanamori H, Mukae J, Ozawa Y, Kondo T, Fukuda T, Ichinohe T, Ota S, Tanaka Y, Murayama T, Kurahashi S, Sakura T, Usui N, Ohtake S, Kiyoi H, Matsumura I, Miyazaki Y, Atsuta Y.	Int J Hematol	2021	114(5):608-19.	WGP 4-25
147	Effect of graft sources on allogeneic hematopoietic stem cell transplantation outcome in adults with chronic myeloid leukemia in the era of tyrosine kinase inhibitors: a Japanese Society of Hematopoietic Cell Transplantation retrospective analysis.	Ohashi K, Nagamura-Inoue T, Nagamura F, Tojo A, Miyamura K, Mori T, Kurokawa M, Taniguchi S, Ishikawa J, Morishima Y, Atsuta Y, Sakamaki H.	Int J Hematol	2014	100(3):296-306.	WGP 6-1
148	Clinical impact of pretransplant use of multiple tyrosine kinase inhibitors on the outcome of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia.	Kondo T, Nagamura-Inoue T, Tojo A, Nagamura F, Uchida N, Nakamae H, Fukuda T, Mori T, Yano S, Kurokawa M, Ueno H, Kanamori H, Hashimoto H, Onizuka M, Takanashi M, Ichinohe T, Atsuta Y, Ohashi K.	Am J Hematol	2017	92(9):902-8.	WGP 6-2
149	Allogeneic hematopoietic stem cell transplantation for the treatment of BCR-ABL1-negative atypical chronic myeloid leukemia and chronic neutrophil leukemia: A retrospective nationwide study in Japan.	Itonaga H, Ota S, Ikeda T, Taji H, Amano I, Hasegawa Y, Ichinohe T, Fukuda T, Atsuta Y, Tanizawa A, Kondo T, Miyazaki Y.	Leuk Res	2018	75:50-7.	WGP 6-3
150	Comparison of Outcomes of Allogeneic Transplantation for Primary Myelofibrosis among Hematopoietic Stem Cell Source Groups.	Murata M, Takenaka K, Uchida N, Ozawa Y, Ohashi K, Kim SW, Ikegame K, Kanda Y, Kobayashi H, Ishikawa J, Ago H, Hirokawa M, Fukuda T, Atsuta Y, Kondo T.	Biol Blood Marrow Transplant	2019	25(8):1536-43.	WGP 6-4
151	Salvage allogeneic stem cell transplantation in patients with pediatric myelodysplastic syndrome and myeloproliferative neoplasms.	Kato M, Yoshida N, Inagaki J, Maeba H, Kudo K, Cho Y, Kurosawa H, Okimoto Y, Tauchi H, Yabe H, Sawada A, Kato K, Atsuta Y, Watanabe K.	Pediatr Blood Cancer	2014	61(10):1860-6.	WGP 7-1
152	Clinical Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation in Children with Juvenile Myelomonocytic Leukemia: A Report from the Japan Society for Hematopoietic Cell Transplantation.	Yoshida N, Sakaguchi H, Yabe M, Hasegawa D, Hama A, Hasegawa D, Kato M, Noguchi M, Terui K, Takahashi Y, Cho Y, Sato M, Koh K, Kakuda H, Shimada H, Hashii Y, Sato A, Kato K, Atsuta Y, Watanabe K; Pediatric Myelodysplastic Syndrome Working Group of the Japan Society for Hematopoietic Cell Transplantation.	Biol Blood Marrow Transplant	2020	26(5):902-10.	WGP 7-2
153	Prognostic value of the revised International Prognostic Scoring System five-group cytogenetic abnormality classification for the outcome prediction of hematopoietic stem cell transplantation in pediatric myelodysplastic syndrome.	Yamamoto S, Kato M, Watanabe K, Ishimaru S, Hasegawa D, Noguchi M, Hama A, Sato M, Koike T, Iwasaki F, Yagasaki H, Takahashi Y, Kosaka Y, Hashii Y, Morimoto A, Atsuta Y, Hasegawa D, Yoshida N.	Bone Marrow Transplant	2021	56(12):3016-23.	WGP 7-3

154	Allogeneic haematopoietic cell transplantation with reduced-intensity conditioning for elderly patients with advanced myelodysplastic syndromes: a nationwide study.	Aoki K, Ishikawa T, Ishiyama K, Aoki J, Itonaga H, Fukuda T, Kakihana K, Uchida N, Ueda Y, Eto T, Mori T, Kondo T, Iwato K, Morishima Y, Tanaka J, Atsuta Y, Miyazaki Y; Adult Myelodysplastic Syndromes Working Group of the Japan Society for Hematopoietic Cell Transplantation (JSHCT).	Br J Haematol	2015	168(3):463-6.	WGP 8-1
155	Effect of Granulocyte Colony-Stimulating Factor-Combined Conditioning in Cord Blood Transplantation for Myelodysplastic Syndrome and Secondary Acute Myeloid Leukemia: A Retrospective Study in Japan.	Konuma T, Takahashi S, Uchida N, Kuwatsuka Y, Yamasaki S, Aoki J, Onishi Y, Aotsuka N, Ohashi K, Mori T, Masuko M, Nakamae H, Miyamura K, Kato K, Atsuta Y, Kato S, Asano S, Takami A, Miyazaki Y; Adult Myelodysplastic Syndrome and Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation.	Biol Blood Marrow Transplant	2015	21(9):1632-40.	WGP 8-2
156	Impacts of graft-versus-host disease on outcomes after allogeneic hematopoietic stem cell transplantation for chronic myelomonocytic leukemia: A nationwide retrospective study.	Itonaga H, Iwanaga M, Aoki K, Aoki J, Ishiyama K, Ishikawa T, Sakura T, Fukuda T, Najima Y, Yujiri T, Mori T, Kurokawa M, Nawa Y, Uchida N, Morishita Y, Hashimoto H, Eto T, Hirokawa M, Morishima Y, Nagamura-Inoue T, Atsuta Y, Miyazaki Y.	Leuk Res	2016	41:48-55.	WGP 8-3
157	Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Myelodysplastic Syndrome Harboring Trisomy 8.	Konuma T, Miyazaki Y, Uchida N, Ohashi K, Kondo T, Nakamae H, Takahashi S, Mori T, Ozawa Y, Kato C, Iwato K, Fukuda T, Ichinohe T, Atsuta Y, Ishiyama K; Adult Myelodysplastic Syndrome Working Group of the Japan Society for Hematopoietic Cell Transplantation.	Biol Blood Marrow Transplant	2017	23(1):75-80.	WGP 8-4
158	Prognostic Impact of Donor Source on Allogeneic Hematopoietic Stem Cell Transplantation Outcomes in Adults with Chronic Myelomonocytic Leukemia: A Nationwide Retrospective Analysis in Japan.	Itonaga H, Aoki K, Aoki J, Ishikawa T, Ishiyama K, Uchida N, Sakura T, Ohashi K, Kurokawa M, Ozawa Y, Matsuoka KI, Nakamura Y, Kimura F, Iwato K, Nawa Y, Hirokawa M, Kato K, Ichinohe T, Atsuta Y, Miyazaki Y.	Biol Blood Marrow Transplant	2018	24(4):840-8.	WGP 8-5
159	Clinical impact of the loss of chromosome 7q on outcomes of patients with myelodysplastic syndromes treated with allogeneic hematopoietic stem cell transplantation.	Itonaga H, Ishiyama K, Aoki K, Aoki J, Ishikawa T, Ohashi K, Fukuda T, Ozawa Y, Ota S, Uchida N, Eto T, Iwato K, Ohno Y, Takanashi M, Ichinohe T, Atsuta Y, Miyazaki Y.	Bone Marrow Transplant	2019	54(9):1471-81.	WGP 8-6
160	Outcomes of second allogeneic haematopoietic stem cell transplantation in patients with relapse of myelodysplastic syndrome.	Shimomura Y, Hara M, Tachibana T, Ohashi K, Sakura T, Fukuda T, Nakazawa H, Iwato K, Kanda Y, Ikeda T, Eto T, Kanda J, Ichinohe T, Atsuta Y, Ishikawa T1, Ishiyama K.	Br J Haematol	2019	138(1):86-90.	WGP 8-7
161	Increased opportunity for prolonged survival after allogeneic hematopoietic stem cell transplantation in patients aged 60-69 years with myelodysplastic syndrome.	Itonaga H, Ishiyama K, Aoki K, Aoki J, Ishikawa T, Uchida N, Ohashi K, Ueda Y, Fukuda T, Sakura T, Ohno Y, Iwato K, Okumura H, Kondo T, Ichinohe T, Takanashi M, Atsuta Y, Miyazaki Y.	Ann Hematol	2019	98(6):1367-81.	WGP 8-8
162	Graft-versus-MDS effect after unrelated cord blood transplantation: a retrospective analysis of 752 patients registered at the Japanese Data Center for Hematopoietic Cell Transplantation.	Ishiyama K, Aoki J, Itonaga H, Uchida N, Takahashi S, Ohno Y, Matsuhashi Y, Sakura T, Onizuka M, Miyakoshi S, Takanashi M, Fukuda T, Atsuta Y, Nakao S, Miyazaki Y.	Blood Cancer J	2019	9(3):31.	WGP 8-9
163	Induction chemotherapy followed by allogeneic HCT versus upfront allogeneic HCT for advanced myelodysplastic syndrome: A propensity score matched analysis.	Konuma T, Shimomura Y, Ozawa Y, Ueda Y, Uchida N, Onizuka M, Akiyama M, Mori T, Nakamae H, Ohno Y, Shiratori S, Onishi Y, Kanda Y, Fukuda T, Atsuta Y, Ishiyama K; Adult Myelodysplastic Syndrome Working Group of the Japan Society for Hematopoietic Cell Transplantation.	Hematologica Oncology	2019	37(1):85-95.	WGP 8-10

164	Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Myelodysplastic/Myeloproliferative Neoplasms–Unclassifiable: A Retrospective Nationwide Study of the Japan Society for Hematopoietic Cell Transplantation.	Kurosawa S, Shimomura Y, Tachibana T, Ishiyama K, Ota S, Kobayashi T, Uchida N, Fukushima K, Ashida T, Matsuoka KI, Kanda J, Ichinohe T, Atsuta Y, Murata M, Aoki J.	Biol Blood Marrow Transplant	2020	26(9):1607–11.	WGP 8–11
165	Effects of Acute and Chronic Graft–versus–myelodysplastic Syndrome on Long–term Outcomes Following Allogeneic Hematopoietic Cell Transplantation.	Konuma T, Ishiyama K, Igarashi A, Uchida N, Ozawa Y, Fukuda T, Ueda Y, Matsuoka KI, Mori T, Katayama Y, Onizuka M, Ichinohe T, Atsuta Y; Adult Myelodysplastic Syndrome Working Group of the Japan Society for Hematopoietic Cell Transplantation.	Clin Cancer Res	2020	26(24):6483–93.	WGP 8–12
166	Outcome and Risk Factors for Therapy–Related Myeloid Neoplasms Treated with Allogeneic Stem Cell Transplantation in Japan.	Kida M, Usuki K, Uchida N, Fukuda T, Katayama Y, Kondo T, Eto T, Matsuoka KI, Matsuhashi Y, Ota S, Sawa M, Miyamoto T, Ichinohe T, Kimura T, Atsuta Y, Takami A, Miyazaki Y, Yano S, Ishiyama K, Yanada M, Aoki J.	Biol Blood Marrow Transplant	2020	26(8):1543–51.	WGP 8–13
167	Fludarabine/busulfan versus busulfan/cyclophosphamide as myeloablative conditioning for myelodysplastic syndrome: a propensity score–matched analysis.	Kurosawa S, Shimomura Y, Itonaga H, Najima Y, Kobayashi T, Ozawa Y, Kanda Y, Kako S, Kawakita T, Matsuoka KI, Maruyama Y, Ota S, Nakazawa H, Imada K, Kanda J, Fukuda T, Atsuta Y, Aoki J.	Bone Marrow Transplant	2021	56(12):3008–15.	WGP 8–14
168	Pretransplantation Red Blood Cell and Platelet Transfusion Burden in De Novo Myelodysplastic Syndrome Undergoing Allogeneic Transplantation.	Konuma T, Aoki J, Ozawa Y, Uchida N, Kobayashi T, Onizuka M, Katayama Y, Ohta T, Nakano N, Ota S, Onishi Y, Kobayashi H, Fukuda T, Kanda Y, Atsuta Y; Adult Myelodysplastic Syndrome Working Group of the Japan Society for Hematopoietic Cell Transplantation.	Transplant Cell Ther	2021	27(8):671–8.	WGP 8–15
169	Allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome in adolescent and young adult patients.	Shimomura Y, Hara M, Konuma T, Itonaga H, Doki N, Ozawa Y, Eto T, Uchida N, Aoki J, Kato J, Onishi Y, Takahashi S, Fukushima K, Nakamae H, Kawakita T, Tanaka J, Fukuda T, Atsuta Y, Ishikawa T, Ishiyama K.	Bone Marrow Transplant	2021	56(10):2510–7.	WGP 8–16
170	Stem cell transplantation for paediatric patients with non–anaplastic peripheral T–cell lymphoma in Japan.	Kobayashi R, Fujita N, Mitsui T, Iwasaki F, Suzumiya J, Kuroda H, Nishimura R, Sasahara Y, Takeshita Y, Kato K, Okumura H, Sakamaki H, Yabe H, Kawa K, Kato K, Suzuki R.	Br J Haematol	2012	159(1):88–93.	WGP 9–1
171	Haematopoietic stem cell transplantation for relapsed or refractory anaplastic large cell lymphoma: a study of children and adolescents in Japan.	Fukano R, Mori T, Kobayashi R, Mitsui T, Fujita N, Iwasaki F, Suzumiya J, Chin M, Goto H, Takahashi Y, Hara J, Park YD, Inoue M, Koga Y, Inagaki J, Sakamaki H, Adachi S, Kawa K, Kato K, Suzuki R.	Br J Haematol	2015	168(4):557–63.	WGP 9–2
172	Outcome differences between children and adolescents and young adults with non–Hodgkin lymphoma following stem cell transplantation.	Kobayashi R, Mitsui T, Fujita N, Osumi T, Aoki T, Aoki K, Suzuki R, Fukuda T, Miyamoto T, Kato K, Nakamae H, Goto H, Eto T, Inoue M, Mori T, Terui K, Onizuka M, Koh K, Koga Y, Ichinohe T, Sawada A, Atsuta Y, Suzumiya J.	Int J Hematol	2017	105(3):369–76.	WGP 9–3
173	Hematopoietic stem cell transplantation in children and adolescents with relapsed or refractory B–cell non–Hodgkin lymphoma.	Fujita N, Kobayashi R, Atsuta Y, Iwasaki F, Suzumiya J, Sasahara Y, Inoue M, Koh K, Hori T, Goto H, Ichinohe T, Hashii Y, Kato K, Suzuki R, Mitsui T.	Int J Hematol	2019	109(4):483–90.	WGP 9–4
174	The effect of graft–versus–host disease on outcomes after allogeneic stem cell transplantation for refractory lymphoblastic lymphoma in children and young adults.	Mitsui T, Fujita N, Koga Y, Fukano R, Osumi T, Hama A, Koh K, Kakuda H, Inoue M, Fukuda T, Yabe H, Takita J, Shimada A, Hashii Y, Sato A, Atsuta Y, Kanda Y, Suzumiya J, Kobayashi R.	Pediatr Blood Cancer	2020	67(4):e28129.	WGP 9–5
175	The effectiveness of busulfan–based conditioning regimens for stem cell transplantation against lymphomas in children, adolescents, and young adults in Japan.	Hori D, Kobayashi R, Fujita N, Suzumiya J, Suzuki R, Kato K, Kawata T, Fukuda T, Inoue M, Goto H, Hama A, Iwato K, Okumura H, Eto T, Hashii Y, Atsuta Y, Mitsui T.	Pediatr Blood Cancer	2019	66(10):e27918.	WGP 9–6

176	Successful outcome with reduced-intensity condition regimen followed by allogeneic hematopoietic stem cell transplantation for relapsed or refractory anaplastic large-cell lymphoma.	Fukano R, Mori T, Fujita N, Kobayashi R, Mitsui T, Kato K, Suzuki R, Suzumiya J, Fukuda T, Shindo M, Maseki , Shimoyama T, Okada K, Inoue M, Inagaki J, Hashii Y, Sato A, Tabuchi K.	Int J Hematol	2019	110(6):723-8.	WGP 9-7
177	High-dose chemotherapy with autologous stem cell transplantation for elderly patients with relapsed/refractory diffuse large B cell lymphoma: a nationwide retrospective study.	Chihara D, Izutsu K, Kondo E, Sakai R, Mizuta S, Yokoyama K, Kaneko H, Kato K, Hasegawa Y, Chou T, Sugahara H, Henzan H, Sakamaki H, Suzuki R, Suzumiya J.	Biol Blood Marrow Transplant	2014	20(5):684-9.	WGP 10-1
178	The role of hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma.	Kako S, Izutsu K, Kato K, Kim SW, Mori T, Fukuda T, Kobayashi N, Taji H, Hashimoto H, Kondo T, Sakamaki H, Morishima Y, Kato K, Suzuki R, Suzumiya J; Adult Lymphoma Working Group of the Japanese Society for Hematopoietic Cell Transplantation.	Am J Hematol	2015	90(2):132-8.	WGP 10-2
179	Long-term survival following autologous and allogeneic stem cell transplantation for blastic plasmacytoid dendritic cell neoplasm.	Aoki T, Suzuki R, Kuwatsuka Y, Kako S, Fujimoto K, Taguchi J, Kondo T, Ohata K, Ito T, Kamoda Y, Fukuda T, Ichinohe T, Takeuchi K, Izutsu K, Suzumiya J.	Blood	2015	125(23):3559-62.	WGP 10-3
180	Therapy-related acute myeloid leukemia and myelodysplastic syndrome after hematopoietic cell transplantation for lymphoma.	Yamasaki S, Suzuki R, Hatano K, Fukushima K, Iida H, Morishima S, Suehiro Y, Fukuda T, Uchida N, Uchiyama H, Ikeda H, Yokota A, Tsukasaki K, Yamaguchi H, Kuroda J, Nakamae H, Adachi Y, Matsuoka KI, Nakamura Y, Atsuta Y, Suzumiya J.	Bone Marrow Transplant	2017	52(7):969-76.	WGP 10-4
181	Impact of hematopoietic stem cell transplantation in patients with relapsed or refractory marginal zone lymphoma.	Yamasaki S, Chihara D, Yoshida I, Kohda K, Sawa M, Ago H, Togitani K, Ohno Y, Tanaka J, Fukuda T, Atsuta Y, Suzumiya J, Suzuki R.	Ann Hematol	2019	98(6):1521-3.	WGP 10-5
182	Risk factors and timing of autologous stem cell transplantation for patients with peripheral T-cell lymphoma.	Yamasaki S, Chihara D, Kim SW, Kawata T, Mizuta S, Ago H, Chou T, Yamane T, Uchiyama H, Oyake T, Miura K, Saito B, Taji H, Nakamae H, Miyamoto T, Fukuda T, Kanda J, Atsuta Y, Suzuki R.	Int J Hematol	2019	109(2):175-86.	WGP 10-6
183	Impact of hematopoietic stem cell transplantation in patients with relapsed or refractory mantle cell lymphoma.	Yamasaki S, Chihara D, Kim SW, Izutsu K, Iwato K, Fukuda T, Uchida N, Amano I, Nakazawa H, Kuroda J, Hashimoto H, Ichinohe T, Kanda Y, Atsuta Y, Suzumiya J, Suzuki R.	Ann Hematol	2018	97(8):1445-52.	WGP 10-7
184	High-Dose Chemotherapy with Autologous Stem Cell Transplantation in Primary Central Nervous System Lymphoma: Data From the Japan Society for Hematopoietic Cell Transplantation Registry.	Kondo E, Ikeda T, Izutsu K, Chihara D, Shimizu-Koresawa R, Fujii N, Sakai T, Kondo T, Kubo K, Kato Y, Akasaka T, Fukuda T, Ichinohe T, Atsuta Y, Suzumiya J, Suzuki R; Adult Lymphoma Working Group of the Japan Society for Hematopoietic Cell Transplantation.	Biol Blood Marrow Transplant	2019	25(5):899-905.	WGP 10-8
185	Effect of allogeneic hematopoietic cell transplantation for patients with T-prolymphocytic leukemia: a retrospective study from the Adult Lymphoma Working Group of the Japan Society for hematopoietic cell transplantation.	Yamasaki S, Nitta H, Kondo E, Uchida N, Miyazaki T, Ishiyama K, Kiyota M, Matsuoka H, Ichinohe T, Fukuda T, Atsuta Y, Suzumiya J, Suzuki R.	Ann Hematol	2019	98(9):2213-20.	WGP 10-9
186	Clinical outcomes of hepatitis B or C virus infections in patients with malignant lymphoma receiving autologous stem cell transplantation: on behalf of the Adult Lymphoma Working Group of the Japan Society for Haematopoietic Cell Transplantation (JSHCT).	Kato H, Kato K, Kim SW, Fukuda T, Mori T, Sawa M, Ohno Y, Yoshioka S, Iwato Y, Taji H, Onizuka M, Kurahashi S, Ichinohe T, Suzumiya J, Suzuki R.	Br J Haematol	2019	186(6):e170-5.	WGP 10-10
187	Outcome of patients receiving consolidative autologous peripheral blood stem cell transplantation in the frontline treatment of intravascular large B-cell lymphoma: Adult Lymphoma Working Group of the Japan Society for Hematopoietic Cell Transplantation.	Kato K, Mori T, Kim SW, Sawa M, Sakai T, Hashimoto H, Taguchi J, Oyake T, Kurahashi S, Imada K, Ohno H, Tanaka J, Ichinohe T, Atsuta Y, Suzuki R, Suzumiya J.	Bone Marrow Transplant	2019	54(9):1515-7.	WGP 10-11

188	Allogeneic haematopoietic stem cell transplantation for primary mediastinal large B-cell lymphoma patients relapsing after high dose chemotherapy with autologous stem cell transplantation: data from the Japan Society for Haematopoietic Cell Transplantation registry.	Kondo E, Shimizu-Koresawa R, Chihara D, Mizuta S, Izutsu K, Ikegame K, Uchida N, Fukuda T, Ichinohe T, Atsuta Y, Suzuki R; Adult Lymphoma Working Group of the JSHCT.	Br J Haematol	2019	186(6):e219-23.	WGP 10-12
189	Allogeneic stem cell transplantation for patients with aggressive NK-cell leukemia.	Fujimoto A, Ishida F, Izutsu K, Yamasaki S, Chihara D, Suzumiya J, Mitsui T, Doki N, Sakai H, Kobayashi H, Kanda J, Fukuda T, Atsuta Y, Suzuki R.	Bone Marrow Transplant	2021	56(2):347-56.	WGP 10-13
190	Outcome of allogeneic hematopoietic stem cell transplantation for mycosis fungoides and Sézary syndrome.	Mori T, Shiratori S, Suzumiya J, Kurokawa M, Shindo M, Naoyuki U, Katsuto T, Miyamoto T, Morishige S, Hirokawa M, Fukuda T, Atsuta Y, Suzuki R.	Hematologica Oncology	2020	38(3):266-71.	WGP 10-14
191	Hematopoietic stem cell transplantation for diffuse large B-cell lymphoma having 8q24/MYC rearrangement in Japan.	Takahashi T, Suzuki R, Yamamoto G, Nakazawa H, Kurosawa M, Kobayashi T, Okada M, Akasaka T, Kim SW, Fukuda T, Ichinohe T, Atsuta Y, Suzumiya J.	Hematologica Oncology	2021	39(1):66-74.	WGP 10-15
192	Outcome of stem cell transplantation for Waldenström's macroglobulinemia: analysis of the Japan Society for Hematopoietic Cell Transplantation (JSHCT) Lymphoma Working Group.	Sakurai M, Mori T, Uchiyama H, Ago H, Iwato K, Eto T, Iwasaki H, Kawata T, Takamatsu H, Yamasaki S, Takanashi M, Ichinohe T, Atsuta Y, Suzuki R.	Ann Hematol	2020	99(7):1635-42.	WGP 10-16
193	Long-term outcome of childhood aplastic anemia patients who underwent allogeneic hematopoietic SCT from an HLA-matched sibling donor in Japan.	Kikuchi A, Yabe H, Kato K, Koh K, Inagaki J, Sasahara Y, Suzuki R, Yoshida N, Kudo K, Kobayashi R, Tabuchi K, Kawa K, Kojima S.	Bone Marrow Transplant	2013	48(5):657-60.	WGP 11-1
194	First-line treatment for severe aplastic anemia in children: bone marrow transplantation from a matched family donor versus immunosuppressive therapy.	Yoshida N, Kobayashi R, Yabe H, Kosaka Y, Yagasaki H, Watanabe K, Kudo K, Morimoto A, Ohga S, Muramatsu H, Takahashi Y, Kato K, Suzuki R, Ohara A, Kojima S.	Haematologica	2014	99(12):1784-91.	WGP 11-2
195	Bloodstream infection after stem cell transplantation in children with idiopathic aplastic anemia.	Kobayashi R, Yabe H, Kikuchi A, Kudo K, Yoshida N, Watanabe K, Muramatsu H, Takahashi Y, Inoue M, Koh K, Inagaki J, Okamoto Y, Sakamaki H, Kawa K, Kato K, Suzuki R, Kojima S.	Biol Blood Marrow Transplant	2014	20(8):1145-9.	WGP 11-3
196	Second allogeneic hematopoietic stem cell transplantation in children with severe aplastic anemia.	Kudo K, Muramatsu H, Yoshida N, Kobayashi R, Yabe H, Tabuchi K, Kato K, Koh K, Takahashi Y, Hashii Y, Kawano Y, Inoue M, Cho Y, Sakamaki H, Kawa K, Kato K, Suzuki R, Kojima S.	Bone Marrow Transplant	2015	50(10):1312-5.	WGP 11-4
197	Unrelated cord blood transplantation in aplastic anemia: is antithymocyte globulin indispensable for conditioning?	Kudo K, Muramatsu H, Narita A, Yoshida N, Kobayashi R, Yabe H, Endo M, Inoue M, Hara J, Kounami S, Inagaki J, Hashii Y, Kato K, Tabuchi K, Kojima S.	Bone Marrow Transplant	2017	52(12):1659-61.	WGP 11-5
198	Conditioning Regimen for Allogeneic Bone Marrow Transplantation in Children With Acquired Bone Marrow Failure: Fludarabine/Melphalan vs. Fludarabine/Cyclophosphamide.	Yoshida N, Takahashi Y, Yabe H, Kobayashi R, Watanabe K, Kudo K, Yabe M, Miyamura T, Koh K, Kawaguchi H, Goto H, Fujita N, Okada K, Okamoto Y, Kato K, Inoue M, Suzuki R, Atsuta Y, Kojima S; Pediatric Aplastic Anemia Working Group of the Japan Society for Hematopoietic Cell Transplantation.	Bone Marrow Transplant	2020	55(7):1272-81.	WGP 11-6
199	Impact of cyclophosphamide dose of conditioning on the outcome of allogeneic hematopoietic stem cell transplantation for aplastic anemia from human leukocyte antigen-identical sibling.	Mori T, Koh H, Onishi Y, Kako S, Onizuka M, Kanamori H, Ozawa Y, Kato C, Iida H, Suzuki R, Ichinohe T, Kanda Y, Maeda T, Nakao S, Yamazaki H.	Int J Hematol	2016	103(4):461-8.	WGP 12-1

200	Outcome of Second Transplantation Using Umbilical Cord Blood for Graft Failure after Allogeneic Hematopoietic Stem Cell Transplantation for Aplastic Anemia.	Onishi Y, Mori T, Kako S, Koh H, Uchida N, Kondo T, Kobayashi T, Yabe H, Miyamoto T, Kato K, Suzuki R, Nakao S, Yamazaki H; Adult Aplastic Anemia Working Group of the Japan Society for Hematopoietic Cell Transplantation.	Biol Blood Marrow Transplant	2017	23(12):2137-42.	WGP 12-2
201	Outcome of allogeneic hematopoietic stem cell transplantation in adult patients with hepatitis-associated aplastic anemia.	Mori T, Onishi Y, Ozawa Y, Kato C, Kai T, Kanda Y, Kurokawa M, Tanaka M, Ashida T, Sawayama Y, Fukuda T, Ichinohe T, Atsuta Y, Yamazaki H.	Int J Hematol	2019	109(6):711-7.	WGP 12-3
202	Mixed Chimerism and Secondary Graft Failure in Allogeneic Hematopoietic Stem Cell Transplantation for Aplastic Anemia.	Kako S, Yamazaki H, Ohashi K, Ozawa Y, Ota S, Kanda Y, Maeda T, Kato J, Ishiyama K, Matsuoka KI, Miyamoto T, Iida H, Ikegame K, Fukuda T, Ichinohe T, Atsuta Y, Mori T; Adult Aplastic Anemia Working Group of the Japanese Society for Hematopoietic Cell Transplantation.	Biol Blood Marrow Transplant	2020	26(3):445-50.	WGP 12-4
203	Cyclosporine/methotrexate versus tacrolimus/methotrexate with or without anti-thymocyte globulin as GVHD prophylaxis in adult patients with aplastic anemia.	Onishi Y, Mori T, Yamazaki H, Takenaka K, Yamaguchi H, Shingai N, Ozawa Y, Iida H, Ota S, Uchida N, Miyamoto T, Katayama Y, Kato J, Yoshioka S, Onizuka M, Ichinohe T, Atsuta Y; Adult Aplastic Anemia Working Group of the Japan Society for Hematopoietic Cell Transplantation.	Ann Hematol	2021	100(1):217-28.	WGP 12-5
204	Outcome of allogeneic hematopoietic stem cell transplantation in adult patients with paroxysmal nocturnal hemoglobinuria.	Nakamura Y, Takenaka K, Yamazaki H, Onishi Y, Ozawa Y, Ikegame K, Matsuoka KI, Toubai T, Ueda Y, Kanda Y, Ichinohe T, Atsuta Y, Mori T.	Int J Hematol	2021	113(1):122-7.	WGP 12-6
205	Total body irradiation-containing conditioning regimens without antithymocyte globulin in adults with aplastic anemia undergoing umbilical cord blood transplantation.	Hiramoto N, Yamazaki H, Nakamura Y, Uchida N, Murata M, Kondo T, Yoshioka S, Eto T, Nishikawa A, Kimura T, Ichinohe T, Atsuta Y, Onishi Y, Suzuki R, Mori T; Adult Aplastic Anemia Working Group of the Japanese Society for Hematopoietic Cell Transplantation.	Ann Hematol	2022	101(1):165-75.	WGP 12-7
206	Allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia-lymphoma with special emphasis on preconditioning regimen: a nationwide retrospective study.	Ishida T, Hishizawa M, Kato K, Tanosaki R, Fukuda T, Taniguchi S, Eto T, Takatsuka Y, Miyazaki Y, Moriuchi Y, Hidaka M, Akashi K, Uike N, Sakamaki H, Morishima Y, Kato K, Suzuki R, Nishiyama T, Utsunomiya A.	Blood	2012	120(8):1734-41.	WGP 13-1
207	Impact of graft-versus-host disease on allogeneic hematopoietic cell transplantation for adult T cell leukemia-lymphoma focusing on preconditioning regimens: nationwide retrospective study.	Ishida T, Hishizawa M, Kato K, Tanosaki R, Fukuda T, Takatsuka Y, Eto T, Miyazaki Y, Hidaka M, Uike N, Miyamoto T, Tsudo M, Sakamaki H, Morishima Y, Suzuki R, Utsunomiya A.	Biol Blood Marrow Transplant	2013	19(12):1731-9.	WGP 13-2
208	Treatment of patients with adult T cell leukemia/lymphoma with cord blood transplantation: a Japanese nationwide retrospective survey.	Kato K, Choi I, Wake A, Uike N, Taniguchi S, Moriuchi Y, Miyazaki Y, Nakamae H, Oku E, Murata M, Eto T, Akashi K, Sakamaki H, Kato K, Suzuki R, Yamanaka T, Utsunomiya A.	Biol Blood Marrow Transplant	2014	20(12):1968-74.	WGP 13-3
209	Early application of related SCT might improve clinical outcome in adult T-cell leukemia/lymphoma.	Fuji S, Fujiwara H, Nakano N, Wake A, Inoue Y, Fukuda T, Hidaka M, Moriuchi Y, Miyamoto T, Uike N, Taguchi J, Eto T, Tomoyose T, Kondo T, Yamanoha A, Ichinohe T, Atsuta Y, Utsunomiya A; ATL Working Group of the Japan Society for Hematopoietic Cell Transplantation.	Bone Marrow Transplant	2016	51(2):205-11.	WGP 13-4

210	Dismal outcome of allogeneic hematopoietic stem cell transplantation for relapsed adult T-cell leukemia/lymphoma, a Japanese nationwide study.	Fujiwara H, Fuji S, Wake A, Kato K, Takatsuka Y, Fukuda T, Taguchi J, Uchida N, Miyamoto T, Hidaka M, Miyazaki Y, Tomoyose T, Onizuka M, Takanashi M, Ichinohe T, Atsuta Y, Utsunomiya A; ATL Working Group of the Japan Society for Hematopoietic Cell Transplantation.	Bone Marrow Transplant	2017	52(3):484-8.	WGP 13-5
211	Risk Assessment in Adult T Cell Leukemia/Lymphoma Treated with Allogeneic Hematopoietic Stem Cell Transplantation.	Yoshimitsu M, Tanosaki R, Kato K, Ishida T, Choi I, Takatsuka Y, Fukuda T, Eto T, Hidaka M, Uchida N, Miyamoto T, Nakashima Y, Moriuchi Y, Nagafuji K, Miyazaki Y, Ichinohe T, Takanashi M, Atsuta Y, Utsunomiya A; ATL Working Group of the Japan Society for Hematopoietic Cell Transplantation.	Biol Blood Marrow Transplant	2018	24(4):832-9.	WGP 13-6
212	The outcome and characteristics of patients with relapsed adult T cell leukemia/lymphoma after allogeneic hematopoietic stem cell transplantation.	Kato K, Uike N, Wake A, Yoshimitsu M, Tobai T, Sawayama Y, Takatsuka Y, Fukuda T, Uchida N, Eto T, Nakashima Y, Kondo T, Taguchi J, Miyamoto T, Nakamae H, Ichinohe T, Kato K, Suzuki R, Utsunomiya A; ATL Working Group of the Japan Society for Hematopoietic Cell Transplantation.	Hematologica Oncology	2019	37(1):54-61.	WGP 13-7
213	A retrospective analysis of haplo-identical HLA-mismatch hematopoietic transplantation without posttransplantation cyclophosphamide for GVHD prophylaxis in patients with adult T-cell leukemia-lymphoma.	Yoshimitsu M, Utsunomiya A, Fuji S, Fujiwara H, Fukuda T, Ogawa H, Takatsuka Y, Ishitsuka K, Yokota A, Okumura H, Ishii K, Nishikawa A, Eto T, Yonezawa A, Miyashita K, Tsukada J, Tanaka J, Atsuta Y, Kato K; ATL Working Group of the Japan Society for Hematopoietic Cell Transplantation.	Bone Marrow Transplant	2019	54(8):1266-74.	WGP 13-8
214	Cytomegalovirus reactivation is associated with increased mortality more than 100 days after allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia/lymphoma.	Sawayama Y, Itonaga H, Fukushima T, Nakano N, Fujiwara H, Utsunomiya A, Fukuda T, Miyamoto T, Eto T, Miyashita K, Nakamae H, Ogata M, Yamanoha A, Miyazaki Y, Kanda J, Atsuta Y, Kato K; ATL Working Group of the Japan Society for Hematopoietic Cell Transplantation.	Am J Hematol	2019	94(5):E143-6.	WGP 13-9
215	Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for ATL with HTLV-1 Antibody-Positive Donors.	Yoshimitsu M, Fuji S, Utsunomiya A, Nakano N, Ito A, Ito Y, Miyamoto T, Suehiro Y, Kawakita T, Moriuchi Y, Nakamae H, Kanda Y, Ichinohe T, Fukuda T, Atsuta Y, Kato K; ATL Working Group of the Japan Society for Hematopoietic Cell Transplantation.	Biol Blood Marrow Transplant	2020	26(4):718-22.	WGP 13-10
216	Does an increased probability of graft-vs-host disease improve the survival of patients with adult T-cell leukemia-lymphoma? A simulation analysis using a Markov model.	Fuji S, Kurosawa S, Inamoto Y, Nakano N, Miyazaki Y, Miyashita K, Hidaka M, Eto T, Uchida N, Ito A, Sawayama Y, Miyamoto T, Suzumiya J, Utsunomiya A, Kanda J, Atsuta Y, Fukuda T, Kato K, on behalf of Adult T-cell Leukemia-Working Group of Japan Society of Hematopoietic Cell Transplantation.	Adv Cell Gene Ther	2019	2:e56.	WGP 13-11
217	GVHD-free, relapse-free survival provides novel clues for optimizing allogeneic-HSCT for adult T-cell leukemia/lymphoma.	Muranushi H, Shindo T, Hishizawa M, Tokunaga M, Wake A, Nakano N, Eto T, Hidaka M, Choi I, Miyamoto T, Uchida N, Moriuchi Y, Miyazaki Y, Fukuda T, Ichinohe T, Atsuta Y; ATL Working Group of the Japanese Society for Hematopoietic Cell Transplantation, Kato K.	Bone Marrow Transplant	2021	56(1):155-66.	WGP 13-12

218	Chromosomal defects and survival in patients with adult T-cell leukemia/lymphoma after allogeneic HSCT.	Nakano N, Utsunomiya A, Matsuo K, Yoshida N, Seto M, Ohshima K, Fujiwara H, Fuji S, Takatsuka Y, Ito A, Miyamoto T, Suehiro Y, Nakamae H, Sawayama Y, Yuasa M, Miyazaki Y, Ota S, Imada K, Fukuda T, Ichinohe T, Atsuta Y, Kato K.	Blood Advances	2021	5(2):475–86.	WGP 13–13
219	Impact of conditioning intensity and regimen on transplant outcomes in patients with adult T-cell leukemia-lymphoma.	Inoue Y, Nakano N, Fuji S, Eto T, Kawakita T, Suehiro Y, Miyamoto T, Sawayama Y, Uchida N, Kondo T, Kanda J, Atsuta Y, Fukuda T, Yoshimitsu M, Kato K; ATL Working Group of the Japan Society for Hematopoietic Cell Transplantation.	Bone Marrow Transplant	2021	56(12):2964–74.	WGP 13–14
220	Long-term follow-up of patients with ATL after autologous stem cell transplantation.	Utsunomiya A, Tokunaga M, Nakano N, Fujiwara H, Miyamoto T, Ogata M, Miyazaki Y, Ishitsuka K, Sakaida E, Taji H, Wakayama T, Ichinohe T, Fukuda T, Atsuta Y, Kato K, Yoshimitsu M.	Bone Marrow Transplant	2022	57(2):323–5.	WGP 13–15
221	Changing trends in prognostic factors for patients with multiple myeloma after autologous stem cell transplantation during the immunomodulator drug/proteasome inhibitor era.	Takamatsu H, Honda S, Miyamoto T, Yokoyama K, Hagiwara S, Ito T, Tomita N, Iida S, Iwasaki T, Sakamaki H, Suzuki R, Sunami K.	Cancer Sci	2015	106(2):179–85.	WGP 14–1
222	Cord Blood Transplantation for Multiple Myeloma: A Study from the Multiple Myeloma Working Group of the Japan Society for Hematopoietic Cell Transplantation.	Kawamura K, Takamatsu H, Ikeda T, Komatsu T, Aotsuka N, Amano I, Yamamoto G, Watanabe K, Ohno Y, Matsue K, Kouzai Y, Tsukada N, Ishiyama K, Anzai N, Kato K, Suzuki R, Sunami K, Kanda Y.	Biol Blood Marrow Transplant	2015	21(7):1291–8.	WGP 14–2
223	Tandem autologous versus autologous/allogeneic transplantation for multiple myeloma: propensity score analysis.	Kawamura K, Ikeda T, Hagiwara S, Mori T, Shinagawa A, Nishiwaki K, Ohashi K, Kubonishi S, Fukuda T, Ito T, Tomita N, Ichinohe T, Kato K, Morishima Y, Atsuta Y, Sunami K, Kanda Y.	Leuk Lymphoma	2016	57(9):2077–83.	WGP 14–3
224	Significance of Salvage Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma: A Nationwide Retrospective Study in Japan.	Muta T, Miyamoto T, Kamimura T, Kanda Y, Nohgawa M, Ueda Y, Iwato K, Sasaki O, Mori T, Uchida N, Iida S, Fukuda T, Atsuta Y, Sunami K.	Acta Haematol	2018	139(1):35–44.	WGP 14–4
225	Clinical Implications of t(11;14) in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation.	Takamatsu H, Yamashita T, Kurahashi S, Saitoh T, Kondo T, Maeda T, Nakazawa H, Murata M, Narita T, Kuroda J, Hashimoto H, Kawamura K, Miyamoto T, Honda S, Ichinohe T, Atsuta Y, Sunami K.	Biol Blood Marrow Transplant	2019	25(3):474–9.	WGP 14–5
226	Efficacy and safety of autologous stem cell transplantation in patients aged ≥ 65 years with multiple myeloma in the era of novel agents.	Mizuno S, Kawamura K, Hanamura I, Sunami K, Mori T, Nakamura F, Iida S, Nakazawa H, Makita M, Kako S, Sawa M, Ueda Y, Takahashi H, Kanda Y, Ichinohe T, Atsuta Y, Takamatsu H, Takami A.	Bone Marrow Transplant	2019	54(10):1595–604.	WGP 14–6
227	Comparison between autologous and allogeneic stem cell transplantation as salvage therapy for multiple myeloma relapsing/progressing after autologous stem cell transplantation.	Ikeda T, Mori K, Kawamura K, Mori T, Hagiwara S, Ueda Y, Kahata K, Uchida N, Tsukada N, Murakami S, Yamamoto M, Takahashi T, Ichinohe T, Onizuka M, Atsuta Y, Kanda Y, Okamoto S, Sunami K, Takamatsu H.	Hematologica Oncology	2019	37(5):586–94.	WGP 14–7
228	Improved survival of multiple myeloma patients treated with autologous transplantation in the modern era of new medicine.	Shimazu Y, Mizuno S, Fuchida SI, Suzuki K, Tsukada N, Hanagaishi A, Itagaki M, Kataoka K, Kako S, Sakaida E, Yoshioka S, Iida S, Doki N, Oyake T, Ichinohe T, Kanda Y, Astuta Y, Takamatsu H; working group of the Japan Society for Transplantation, Cellular Therapy.	Cancer Sci	2021	112(12):5034–45.	WGP 14–8
229	Retrospective Analysis of Autologous Stem Cell Transplantation for AL Amyloidosis: A Study from the Multiple Myeloma Working Group of the Japan Society for Hematopoietic Cell Transplantation.	Fuchida SI, Kawamura K, Sunami K, Tsukada N, Fujii S, Ohkawara H, Usuki K, Wake A, Endo S, Ishiyama K, Ueda Y, Nakamura Y, Miyamoto T, Fukuda T, Ichinohe T, Atsuta Y, Takamatsu H.	Transplant Cell Ther	2022	28(2):76–82.	WGP 14–9

230	Efficacy of high-dose chemotherapy with stem cell transplantation for hepatoblastoma in Japan.	山本将平, 渡邊健一郎, 井上雅美, 橋井佳子, 菊田 敦, 金子 隆, 加藤剛二, 原純一, 田淵 健, 高橋義行.	日本小児血液・がん学会雑誌	2017	54(2):126-32.	WGP 15-1
231	Autologous Stem Cell Transplantation for Children With Renal Tumors, and Adults With Wilms Tumor: Retrospective Analysis of the Japanese Transplant Registry Unified Management Program.	Kobayashi R, Inoue M, Takahashi Y, Kikuta A, Ogawa A, Koga Y, Koh K, Hashii Y, Hara J, Kato K, Tabuchi K, Matsumoto K.	J Pediatr Hematol Oncol	2020	42(4):251-5.	WGP 15-2
232	Effect of high-dose chemotherapy plus stem cell rescue on the survival of patients with neuroblastoma modified by MYCN gene gain/amplification and remission status: a nationwide registration study in Japan.	Saito Y, Urashima M, Takahashi Y, Ogawa A, Kiyotani C, Yuza Y, Koh K, Watanabe K, Kosaka Y, Goto H, Kikuta A, Okada K, Koga Y, Fujimura J, Inoue M, Sato A, Atsuta Y, Matsumoto K.	Bone Marrow Transplant	2021	56(9):2173-82.	WGP 15-3
233	Comparison of second transplantation and donor lymphocyte infusion for donor mixed chimerism after allogeneic stem cell transplantation for nonmalignant diseases.	Umeda K, Adachi S, Tanaka S, Miki M, Okada K, Hashii Y, Inoue M, Cho Y, Koh K, Goto H, Kajiwara R, Hyakuna N, Kato K, Morio T, Yabe H; Inherited Disease Working Group of the Japan Society for Hematopoietic Cell Transplantation.	Pediatr Blood Cancer	2016	63(12):2221-9.	WGP 16-1
234	Allogeneic Hematopoietic Stem Cell Transplantation for Leukocyte Adhesion Deficiency.	Horikoshi Y, Umeda K, Imai K, Yabe H, Sasahara Y, Watanabe K, Ozawa Y, Hashii Y, Kurosawa H, Nonoyama S, Morio T.	J Pediatr Hematol Oncol	2018	40(2):137-40.	WGP 16-2
235	Impact of low-dose irradiation and in vivo T-cell depletion on hematopoietic stem cell transplantation for non-malignant diseases using fludarabine-based reduced-intensity conditioning.	Umeda K, Yabe H, Kato K, Imai K, Kobayashi M, Takahashi Y, Yoshida N, Sato M, Sasahara Y, Kato K, Adachi S, Koga Y, Okada K, Inoue M, Hashii Y, Atsuta Y, Morio T; Inherited Disease Working Group of the Japan Society for Hematopoietic Cell Transplantation.	Bone Marrow Transplant	2019	54(8):1227-36.	WGP 16-3
236	Long-term outcome and chimerism in patients with Wiskott-Aldrich syndrome treated by hematopoietic cell transplantation: a retrospective nationwide survey.	Iguchi A, Cho Y, Yabe H, Kato S, Kato K, Hara J, Koh K, Takita J, Ishihara T, Inoue M, Imai K, Nakayama H, Hashii Y, Morimoto A, Atsuta Y, Morio T; Hereditary disorder Working Group of the Japan Society for Hematopoietic Cell Transplantation.	Int J Hematol	2019	110(3):364-9.	WGP 16-4
237	Impact of Graft-Versus-Host Disease on the Clinical Outcome of Allogeneic Hematopoietic Stem Cell Transplantation for Non-Malignant Diseases.	Umeda K, Imai K, Yanagimachi M, Yabe H, Kobayashi M, Takahashi Y, Kajiwara M, Yoshida N, Cho Y, Inoue M, Hashii Y, Atsuta Y, Morio T; Inherited Disease Working Group of the Japan Society for Hematopoietic Cell Transplantation.	Int J Hematol	2020	111(6):869-76.	WGP 16-5
238	Long-term outcome in patients with Fanconi anemia who received hematopoietic stem cell transplantation: a retrospective nationwide analysis.	Yabe M, Morio T, Tabuchi K, Tomizawa D, Hasegawa D, Ishida H, Yoshida N, Koike T, Takahashi Y, Koh K, Okamoto Y, Sano H, Kato K, Kanda Y, Goto H, Takita J, Miyamura T, Noguchi M, Kato K, Hashii Y, Astuta Y, Yabe H.	Int J Hematol	2021	113(1):134-44.	WGP 16-6
239	Hematopoietic Cell Transplantation for Chronic Granulomatous Disease in Japan.	Yanagimachi M, Kato K, Iguchi A, Sasaki K, Kiyotani C, Koh K, Koike T, Sano H, Shigemura T, Muramatsu H, Okada K, Inoue M, Tabuchi K, Nishimura T, Mizukami T, Nunoi H, Imai K, Kobayashi M, Morio T.	Front Immunol	2020	11:1617.	WGP 16-7
240	Hematopoietic Cell Transplantation for Severe Combined Immunodeficiency Patients: a Japanese Retrospective Study.	Miyamoto S, Umeda K, Kurata M, Nishimura A, Yanagimachi M, Ishimura M, Sato M, Shigemura T, Kato M, Sasahara Y, Iguchi A, Koike T, Takahashi Y, Kajiwara M, Inoue M, Hashii Y, Yabe H, Kato K, Atsuta Y, Imai K, Morio T.	J Clin Immunol	2021	41(8):1865-77.	WGP 16-8
241	Stem cell transplantation for pediatric patients with adrenoleukodystrophy: A nationwide retrospective analysis in Japan.	Kato K, Yabe H, Shimozawa N, Adachi S, Kurokawa M, Hashii Y, Sato A, Yoshida N, Kaga M, Onodera O, Kato S, Atsuta Y, Morio T.	Pediatr Transplant	2022	26(1):e14125.	WGP 16-9

242	Hematopoietic Cell Transplantation for Inborn Errors of Immunity Other than Severe Combined Immunodeficiency in Japan: Retrospective Analysis for 1985–2016.	Miyamoto S, Umeda K, Kurata M, Yanagimachi M, Iguchi A, Sasahara Y, Okada K, Koike T, Tanoshima R, Ishimura M, Yamada M, Sato M, Takahashi Y, Kajiwara M, Kawaguchi H, Inoue M, Hashii Y, Yabe H, Kato K, Atsuta Y, Imai K, Morio T.	J Clin Immunol		in press	WGP 16–10
243	Impact of a single human leucocyte antigen (HLA) allele mismatch on the outcome of unrelated bone marrow transplantation over two time periods. A retrospective analysis of 3003 patients from the HLA Working Group of the Japan Society for Blood and Marrow Transplantation.	Kanda Y, Kanda J, Atsuta Y, Maeda Y, Ichinohe T, Ohashi K, Fukuda T, Miyamura K, Iida H, Mori T, Iwato K, Eto T, Kawa K, Morita S, Morishima Y.	Br J Haematol	2013	161(4):566–77.	WGP 17–1
244	Effects of KIR ligand incompatibility on clinical outcomes of umbilical cord blood transplantation without ATG for acute leukemia in complete remission.	Tanaka J, Morishima Y, Takahashi Y, Yabe T, Oba K, Takahashi S, Taniguchi S, Ogawa H, Onishi Y, Miyamura K, Kanamori H, Aotsuka N, Kato K, Kato S, Atsuta Y, Kanda Y.	Blood Cancer J	2013	3:e164.	WGP 17–2
245	Different effects of HLA disparity on transplant outcomes after single-unit cord blood transplantation between pediatric and adult patients with leukemia.	Atsuta Y, Kanda J, Takahashi M, Morishima Y, Taniguchi S, Takahashi S, Ogawa H, Ohashi K, Ohno Y, Onishi Y, Aotsuka N, Nagamura-Inoue T, Kato K, Kanda Y; HLA Working Group of the Japan Society for Hematopoietic Cell Transplantation.	Haematologica	2013	98(5):814–22.	WGP 17–3
246	Impact of the direction of HLA mismatch on transplantation outcomes in single unrelated cord blood transplantation.	Kanda J, Atsuta Y, Wake A, Ichinohe T, Takahashi M, Morishima Y, Taniguchi S, Takahashi S, Ogawa H, Ohashi K, Ohno Y, Aotsuka N, Onishi Y, Kato K, Nagamura-Inoue T, Kanda Y; HLA Working Group of the Japan Society for Hematopoietic Cell Transplantation.	Biol Blood Marrow Transplant	2013	19(2):247–54.	WGP 17–4
247	Changes in the clinical impact of high-risk human leukocyte antigen allele mismatch combinations on the outcome of unrelated bone marrow transplantation.	Kanda Y, Kanda J, Atsuta Y, Fuji S, Maeda Y, Ichinohe T, Takahashi M, Ohashi K, Fukuda T, Miyamura K, Mori T, Sao H, Kobayashi N, Iwato K, Sawada A, Mori S; HLA working group of the Japan Society for Hematopoietic Cell Transplantation.	Biol Blood Marrow Transplant	2014	20(4):526–35.	WGP 17–5
248	Decision analysis for donor selection in stem cell transplantation—HLA-8/8 allele-matched unrelated donor vs HLA-1 AG mismatched related donor.	Kanda J, Fuji S, Kato S, Takami A, Tanaka J, Miyamura K, Ohashi K, Fukuda T, Ozawa Y, Kanamori H, Eto T, Kobayashi N, Iwato K, Morishima Y, Sakamaki H, Atsuta Y, Kanda Y; HLA Working Group; Donor/Source Working Group; Adult AML Working Group; Adult ALL Working Group of the Japan Society for Hematopoietic Cell Transplantation.	Blood Cancer J	2014	4:e263.	WGP 17–6
249	Impact of HLA allele mismatch on the clinical outcome in serologically matched related hematopoietic SCT.	Fuji S, Kanda J, Kato S, Ikegame K, Morishima S, Miyamoto T, Hidaka M, Kubo K, Miyamura K, Ohashi K, Kobayashi H, Maesako Y, Adachi S, Ichinohe T, Atsuta Y, Kanda Y; HLA Working Group of Japan Society for Hematopoietic Cell Transplantation.	Bone Marrow Transplant	2014	49(9):1187–92.	WGP 17–7
250	Impact of HLA mismatch direction on the outcome of unrelated bone marrow transplantation: a retrospective analysis from the Japan Society for Hematopoietic Cell Transplantation.	Kanda J, Ichinohe T, Fuji S, Maeda Y, Ohashi K, Fukuda T, Miyamura K, Iwato K, Eto T, Nakamae H, Kobayashi N, Mori T, Mori S, Morishima Y, Atsuta Y, Kanda Y; HLA Working Group of the Japan Society for Hematopoietic Cell Transplantation.	Biol Blood Marrow Transplant	2015	21(2):305–11.	WGP 17–8

251	A single high-resolution HLA mismatch has a similar adverse impact on the outcome of related hematopoietic stem cell transplantation as a single low-resolution HLA mismatch.	Fuji S, Kanda J, Kato S, Ikegame K, Morishima S, Miyamoto T, Hidaka M, Kubo K, Miyamura K, Tsudo M, Kobayashi H, Maesako Y, Eto T, Adachi S, Ichinohe T, Atsuta Y, Kanda Y; HLA Working Group of the Japan Society for Hematopoietic Cell Transplantation.	Am J Hematol	2015	90(7):618-23.	WGP 17-9
252	Unrelated bone marrow transplantation or immediate umbilical cord blood transplantation for patients with acute myeloid leukemia in first complete remission.	Yanada M, Kanda J, Ohtake S, Fukuda T, Sakamaki H, Miyamura K, Miyawaki S, Uchida N, Maeda T, Nagamura-Inoue T, Asou N, Morishima Y, Atsuta Y, Miyazaki Y, Kimura F, Kobayashi Y, Takami A, Naoe T, Kanda Y.	Eur J Haematol	2016	97(3):278-87.	WGP 17-10
253	Influence of Differently Licensed KIR2DL1-Positive Natural Killer Cells in Transplant Recipients with Acute Leukemia: A Japanese National Registry Study.	Arima N, Nakamura F, Yabe T, Tanaka J, Fuji S, Ohashi K, Fukuda T, Miyamura K, Iwato K, Eto T, Mori T, Kobayashi N, Hoshino T, Kato C, Kanamori H, Nakamae H, Atsuta Y, Morishima Y, Kanda Y.	Biol Blood Marrow Transplant	2016	22(3):423-31.	WGP 17-11
254	Haploidentical and Matched Sibling Donor Hematopoietic Cell Transplantation for Patients with HLA-Homozygous Haplotypes.	Kanda J, Ikegame K, Fuji S, Kurokawa M, Kanamori H, Fukuda T, Ohashi K, Ishikawa J, Ogawa H, Inoue M, Ichinohe T, Atsuta Y, Kanda Y; HLA Working Group of the Japan Society for Hematopoietic Cell Transplantation.	Biol Blood Marrow Transplant	2016	22(11):2031-7.	WGP 17-12
255	Impact of Human Leukocyte Antigen Allele Mismatch in Unrelated Bone Marrow Transplantation with Reduced-Intensity Conditioning Regimen.	Yokoyama H, Kanda J, Fuji S, Kim SW, Fukuda T, Najima Y, Ohno H, Uchida N, Ueda Y, Eto T, Iwato K, Kobayashi H, Ozawa Y, Kondo T, Ichinohe T, Atsuta Y, Kanda Y; HLA Working Group of the Japan Society for Hematopoietic Cell Transplantation.	Biol Blood Marrow Transplant	2017	23(2):300-9.	WGP 17-13
256	Impact of the presence of HLA 1-locus mismatch and the use of low-dose antithymocyte globulin in unrelated bone marrow transplantation.	Kawamura K, Kanda J, Fuji S, Murata M, Ikegame K, Yoshioka K, Fukuda T, Ozawa Y, Uchida N, Iwato K, Sakura T, Hidaka M, Hashimoto H, Ichinohe T, Atsuta Y, Kanda Y.	Bone Marrow Transplant	2017	52(10):1390-8.	WGP 17-14
257	Homozygous HLA-C1 is Associated with Reduced Risk of Relapse after HLA-Matched Transplantation in Patients with Myeloid Leukemia.	Arima N, Kanda J, Tanaka J, Yabe T, Morishima Y, Kim SW, Najima Y, Ozawa Y, Eto T, Kanamori H, Mori T, Kobayashi N, Kondo T, Nakamae H, Uchida N, Inoue M, Fukuda T, Ichinohe T, Atsuta Y, Kanda Y.	Biol Blood Marrow Transplant	2018	24(4):717-25.	WGP 17-15
258	Comparison of HLA Allele Mismatch and Antigen Mismatch in Unrelated Bone Marrow Transplantation in Patients with Leukemia.	Atsuta Y, Kato S, Morishima Y, Ohashi K, Fukuda T, Ozawa Y, Eto T, Iwato K, Uchida N, Ota S, Onizuka M, Ichinohe T, Kanda J, Kanda Y; HLA Working Group of the Japan Society for Hematopoietic Cell Transplantation.	Biol Blood Marrow Transplant	2019	25(3):436-42.	WGP 17-16
259	HLA discrepancy between graft and host rather than that graft and first donor impact the second transplant outcome.	Maeda Y, Ugai T, Kondo E, Ikegame K, Murata M, Uchida N, Miyamoto T, Takahashi S, Ohashi K, Nakamae H, Fukuda T, Onizuka M, Eto T, Ota S, Hirokawa M, Ichinohe T, Atsuta Y, Kanda Y, Kanda J.	Haematologica	2019	104(5):1055-61.	WGP 17-17
260	Effects of HLA mismatch on cytomegalovirus reactivation in cord blood transplantation.	Yokoyama H, Kanda J, Kato S, Kondo E, Maeda Y, Saji H, Takahashi S, Onizuka M, Onishi Y, Ozawa Y, Kanamori H, Ishikawa J, Ohno Y, Ichinohe T, Takahashi M, Kato K, Atsuta Y, Kanda Y; HLA Working Group of the Japan Society for Hematopoietic Cell Transplantation.	Bone Marrow Transplant	2019	54(7):1004-12.	WGP 17-18

261	Clinical significance of low-dose total body irradiation in HLA-mismatched reduced-intensity stem cell transplantation.	Fujiwara SI, Kanda J, Tatara R, Ogawa H, Fukuda T, Okumura H, Ohashi K, Iwato K, Ueda Y, Ishiyama K, Eto T, Matsuoka KI, Nakamae H, Onizuka M, Atsuta Y, Kanda Y, HLA Working Group of the Japan Society for Hematopoietic Cell Transplantation.	Bone Marrow Transplant	2019	54(8):1327-36.	WGP 17-19
262	Effects of Haplotype Matching on Outcomes after Adult Single-Cord Blood Transplantation.	Kanda J, Kawase T, Tanaka H, Kojima H, Morishima Y, Uchida N, Nagafuji K, Matsuhashi Y, Ohta T, Onizuka M, Sakura T, Takahashi S, Miyakoshi S, Kobayashi H, Eto T, Tanaka J, Ichinohe T, Atsuta Y, Morishima S; HLA Working Group of the Japan Society for Hematopoietic Cell Transplantation.	Biol Blood Marrow Transplant	2020	26(3):509-18.	WGP 17-20
263	Impact of High-Frequency HLA Haplotypes on Clinical Cytomegalovirus Reactivation in Allogeneic Hematopoietic Stem Cell Transplantation.	Kawase T, Tanaka H, Kojima H, Uchida N, Ohashi K, Fukuda T, Ozawa Y, Ikegame K, Eto T, Mori T, Miyamoto T, Hidaka M, Shiratori S, Takanashi M, Atsuta Y, Ichinohe T, Kanda Y, Kanda J; HLA Working Group of the Japan Society for Hematopoietic Cell Transplantation.	Biol Blood Marrow Transplant	2019	25(12):2482-9.	WGP 17-21
264	Impact of Homozygous Conserved Extended HLA Haplotype on Single Cord Blood Transplantation: Lessons for Induced Pluripotent Stem Cell Banking and Transplantation in Allogeneic Settings.	Morishima Y, Morishima S, Murata M, Arima N, Uchida N, Sugio Y, Takahashi S, Matsuhashi Y, Onizuka M, Eto T, Nagafuji K, Onishi Y, Inoue M, Atsuta Y, Fukuda T, Ichinohe T, Kato S, Kanda J.	Biol Blood Marrow Transplant	2020	26(1):132-8.	WGP 17-22
265	Short-term clinical outcomes after HLA 1-locus mismatched uPBSCT are similar to that after HLA-matched uPBSCT and uBMT.	Fuji S, Miyamura K, Kanda Y, Fukuda T, Kobayashi T, Ozawa Y, Iwato K, Uchida N, Eto T, Ashida T, Mori T, Sawa M, Ichinohe T, Atsuta Y, Kanda J; HLA Working Group of the Japan Society for Hematopoietic Cell Transplantation.	Int J Hematol	2019	109(6):684-93.	WGP 17-23
266	Impact of HLA Allele Mismatch at HLA-A, -B, -C, and -DRB1 in Single Cord Blood Transplantation.	Yokoyama H, Morishima Y, Fuji S, Uchida N, Takahashi S, Onizuka M, Tanaka M, Yuju O, Eto T, Ozawa Y, Takada S, Takanashi M, Kato K, Kanda Y, Ichinohe T, Atsuta Y, Kanda J; HLA Working Group of the Japan Society for Hematopoietic Cell Transplantation.	Biol Blood Marrow Transplant	2020	26(3):519-28.	WGP 17-24
267	Increased Relapse Risk of Acute Lymphoid Leukemia in Homozygous HLA-C1 Patients after HLA-Matched Allogeneic Transplantation: A Japanese National Registry Study.	Arima N, Kanda J, Yabe T, Morishima Y, Tanaka J, Kako S, Sakaguchi H, Kato M, Ohashi K, Ozawa Y, Fukuda T, Ota S, Tachibana T, Onizuka M, Ichinohe T, Atsuta Y, Kanda Y.	Biol Blood Marrow Transplant	2020	26(3):431-7.	WGP 17-25
268	Influence of HLA 1-3-locus mismatch and antithymocyte globulin administration in unrelated bone marrow transplantation.	Kawamura K, Kanda J, Ohashi K, Fukuda T, Iwato K, Eto T, Fujiwara SI, Mori T, Fukushima K, Ozawa Y, Uchida N, Ashida T, Ichinohe T, Atsuta Y, Kanda Y.	Ann Hematol	2020	99(5):1099-110.	WGP 17-26
269	Individual HLAs influence immunological events in allogeneic stem cell transplantation from HLA-identical sibling donors.	Morishima S, Fukuda T, Doki N, Mori T, Onizuka M, Kawakita T, Kato C, Ozawa Y, Tanaka M, Kurokawa M, Kamimura T, Inoue M, Tanaka J, Ichinohe T, Atsuta Y, Morishima Y; HLA Working Group of the Japan Society for Hematopoietic Cell Transplantation.	Bone Marrow Transplant	2021	56(3):646-54.	WGP 17-27
270	Human leukocyte antigen (HLA) haplotype matching in unrelated single HLA allele mismatch bone marrow transplantation.	Kawajiri A, Kawase T, Tanaka H, Fukuda T, Mukae J, Ozawa Y, Eto T, Uchida N, Mori T, Ashida T, Kondo T, Onizuka M, Ichinohe T, Atsuta Y, Morishima S, Kanda J; HLA Working Group of the Japan Society for Hematopoietic Cell Transplantation.	Bone Marrow Transplant		in press	WGP 17-28

271	Low-dose antithymocyte globulin inhibits chronic graft-versus-host disease in peripheral blood stem cell transplantation from unrelated donors.	Shiratori S, Sugita J, Fuji S, Aoki J, Sawa M, Ozawa Y, Hashimoto D, Matsuoka KI, Imada K, Doki N, Ashida T, Ueda Y, Tanaka M, Sawayama Y, Ichinohe T, Terakura S, Morishima S, Atsuta Y, Fukuda T, Teshima T.	Bone Marrow Transplant	2021	56(9):223 1-40.	WGP 17-29
272	Impact of HLA disparity on the risk of overall mortality in patients with grade II-IV acute GVHD on behalf of the HLA Working Group of Japan Society for Hematopoietic Cell Transplantation.	Fuji S, Hakoda A, Kanda J, Murata M, Terakura S, Inamoto Y, Uchida N, Toya T, Eto T, Nakamae H, Ikegame K, Tanaka M, Kawakita T, Kondo T, Miyamoto T, Fukuda T, Ichinohe T, Kimura T, Atsuta Y, Shintani A, Morishima S.	Bone Marrow Transplant	2021	56(12):29 90-6.	WGP 17-30
273	Reduced leukemia relapse through cytomegalovirus reactivation in killer cell immunoglobulin-like receptor-ligand-mismatched cord blood transplantation.	Yokoyama H, Kanda J, Kawahara Y, Uchida N, Tanaka M, Takahashi S, Onizuka M, Noguchi Y, Ozawa Y, Katsuoka Y, Ota S, Ohta T, Kimura T, Kanda Y, Ichinohe T, Atsuta Y, Nakasone H, Morishima S.	Bone Marrow Transplant	2021	56(6):135 2-63.	WGP 17-31
274	Altered effect of killer immunoglobulin-like receptor-ligand mismatch by graft versus host disease prophylaxis in cord blood transplantation.	Yokoyama H, Hirayama M, Takahashi Y, Uchida N, Tanaka M, Onizuka M, Ozawa Y, Onai D, Katsuoka Y, Wake A, Sawa M, Kobayashi H, Maruyama Y, Ozeki K, Kimura T, Kanda J, Fukuda T, Atsuta Y, Terakura S, Morishima S.	Bone Marrow Transplant	2021	56(12):30 59-67.	WGP 17-32
275	Unrelated cord blood transplantation vs related transplantation with HLA 1-antigen mismatch in the graft-versus-host direction.	Kanda J, Ichinohe T, Kato S, Uchida N, Terakura S, Fukuda T, Hidaka M, Ueda Y, Kondo T, Taniguchi S, Takahashi S, Nagamura-Inoue T, Tanaka J, Atsuta Y, Miyamura K, Kanda Y; Donor/Source Working Group and HLA Working Group of the Japan Society for Hematopoietic Cell Transplantation.	Leukemia	2013	27(2):286 -94.	WGP 18-1
276	Graft-versus-host disease and survival after cord blood transplantation for acute leukemia: a comparison of Japanese versus White populations.	Kuwatsuka Y, Atsuta Y, Horowitz MM, Inagaki J, Kanda J, Kato K, Koh K, Zhang MJ, Eapen M; Center for International Blood and Marrow Transplant Research (CIBMTR), and Donor/Source and GVHD Working Group of the Japan Society for Hematopoietic Cell Transplantation (JSHCT).	Biol Blood Marrow Transplant	2014	20(5):662 -7.	WGP 18-2
277	Comparison of cord blood transplantation with unrelated bone marrow transplantation in patients older than fifty years.	Tanaka M, Miyamura K, Terakura S, Imai K, Uchida N, Ago H, Sakura T, Eto T, Ohashi K, Fukuda T, Taniguchi S, Mori S, Nagamura-Inoue T, Atsuta Y, Okamoto S.	Biol Blood Marrow Transplant	2015	21(3):517 -25.	WGP 18-3
278	Comparison of Outcomes of 8/8 and 7/8 Allele-Matched Unrelated Bone Marrow Transplantation and Single-Unit Cord Blood Transplantation in Adults with Acute Leukemia.	Terakura S, Atsuta Y, Tsukada N, Kobayashi T, Tanaka M, Kanda J, Najima Y, Fukuda T, Uchida N, Takahashi S, Nagamura-Inoue T, Morishima Y, Miyamura K; Japan Society for Hematopoietic Cell Transplantation.	Biol Blood Marrow Transplant	2016	22(2):330 -8.	WGP 18-4
279	Comparing Outcomes with Bone Marrow or Peripheral Blood Stem Cells as Graft Source for Matched Sibling Transplants in Severe Aplastic Anemia across Different Economic Regions.	Kumar R, Kimura F, Ahn KW, Hu ZH, Kuwatsuka Y, Klein JP, Pasquini M, Miyamura K, Kato K, Yoshimi A, Inamoto Y, Ichinohe T, Wood WA Jr, Wirk B, Seftel M, Rowlings P, Marks DI, Schultz KR, Gupta V, Dedeken L, George B, Cahn JY, Szer J, Lee JW, Ho AY, Fasth A, Hahn T, Khera N, Dalal J, Bonfim C, Aljurf M, Atsuta Y, Saber W.	Biol Blood Marrow Transplant	2016	22(5):932 -40.	WGP 18-5
280	Graft-versus-Host Disease after HLA-Matched Sibling Bone Marrow or Peripheral Blood Stem Cell Transplantation: Comparison of North American Caucasian and Japanese Populations.	Kanda J, Brazauskas R, Hu ZH, Kuwatsuka Y, Nagafuji K, Kanamori H, Kanda Y, Miyamura K, Murata M, Fukuda T, Sakamaki H, Kimura F, Seo S, Aljurf M, Yoshimi A, Milone G, Wood WA, Ustun C, Hashimi S, Pasquini M, Bonfim C, Dalal J, Hahn T, Atsuta Y, Saber W.	Biol Blood Marrow Transplant	2016	22(4):744 -51.	WGP 18-6

281	Comparison of Donor Sources in Hematopoietic Stem Cell Transplantation for Childhood Acute Leukemia: A Nationwide Retrospective Study.	Sakaguchi H, Watanabe N, Matsumoto K, Yabe H, Kato S, Ogawa A, Inagaki J, Goto H, Koh K, Yoshida N, Kato K, Cho Y, Kosaka Y, Takahashi Y, Inoue M, Kato K, Atsuta Y, Miyamura K; Donor/Source Working Group of Japan Society of Hematopoietic Cell Transplantation.	Biol Blood Marrow Transplant	2016	22(12):22 26-34.	WGP 18-7
282	A Comparison of Outcomes for Cord Blood Transplantation and Unrelated Bone Marrow Transplantation in Adult Aplastic Anemia.	Kuwatsuka Y, Kanda J, Yamazaki H, Mori T, Miyamura K, Kako S, Uchida N, Ohashi K, Ozawa Y, Takahashi Y, Kato C, Iwato K, Ishiyama K, Kobayashi H, Eto T, Kahata K, Kato J, Miyamoto T, Kato K, Mori S, Atsuta Y, Kimura F, Kanda Y; Japan Society for Hematopoietic Cell Transplantation.	Biol Blood Marrow Transplant	2016	22(10):18 36-43.	WGP 18-8
283	Comparison of transplant outcomes from matched sibling bone marrow or peripheral blood stem cell and unrelated cord blood in patients 50 years or older.	Konuma T, Tsukada N, Kanda J, Uchida N, Ohno Y, Miyakoshi S, Kanamori H, Hidaka M, Sakura T, Onizuka M, Kobayashi N, Sawa M, Eto T, Matsuhashi Y, Kato K, Ichinohe T, Atsuta Y, Miyamura K; Donor/Source Working Group of the Japan Society for Hematopoietic Cell Transplantation.	Am J Hematol	2016	91(5):E28 4-92.	WGP 18-9
284	ABO blood type incompatibility lost the unfavorable impact on outcome in unrelated bone marrow transplantation.	Kimura F, Kanda J, Ishiyama K, Yabe T, Yoshifuji K, Fukuda T, Ozawa Y, Iwato K, Eto T, Mori T, Uchida N, Ota S, Sakura T, Ichinohe T, Atsuta Y, Kanda Y; donor/source working group of the Japan Society for Hematopoietic Cell Transplantation.	Bone Marrow Transplant	2019	54(10):16 76-85.	WGP 18-10
285	Prognostic factors for adult single cord blood transplantation among European and Japanese populations: the Eurocord/ALWP-EBMT and JSHCT/JDCHCT collaborative study.	Kanda J, Hayashi H, Ruggeri A, Kimura F, Volt F, Takahashi S, Labopin M, Kako S, Tozatto-Maio K, Yano S, Sanz G, Uchida N, Van Lint MT, Kato S, Mohty M, Forcade E, Kanamori H, Sierra J, Ohno Y, Saccardi R, Fukuda T, Ichinohe T, Takahashi M, Rocha V, Okamoto S, Nagler A, Atsuta Y, Gluckman E.	Leukemia	2020	34(1):128 -37.	WGP 18-11
286	Improvement of early mortality in single-unit cord blood transplantation for Japanese adults from 1998 to 2017.	Konuma T, Kanda J, Inamoto Y, Hayashi H, Kobayashi S, Uchida N, Sugio Y, Tanaka M, Kobayashi H, Kouzai Y, Takahashi S, Eto T, Mukae J, Matsuhashi Y, Fukuda T, Takahashi M, Kanda Y, Atsuta Y, Kimura F.	Am J Hematol	2020	95(4):343 -53.	WGP 18-12
287	Comparison of Reduced-Intensity/Toxicity Conditioning Regimens for Umbilical Cord Blood Transplantation for Lymphoid Malignancies.	Imahashi N, Terakura S, Kondo E, Kako S, Uchida N, Kobayashi H, Inamoto Y, Sakai H, Tanaka M, Ishikawa J, Kozai Y, Matsuoka KI, Kimura T, Fukuda T, Atsuta Y, Kanda J; Donor/Source Working Group of the Japan Society for Hematopoietic Cell Transplantation.	Bone Marrow Transplant	2020	55(11):20 98-108.	WGP 18-13
288	Updated Comparison of 7/8 HLA Allele-Matched Unrelated Bone Marrow Transplantation and Single-Unit Umbilical Cord Blood Transplantation as Alternative Donors in Adults with Acute Leukemia.	Miyao K, Terakura S, Kimura F, Konuma T, Miyamura K, Yanada M, Kako S, Morishima S, Uchida N, Toya T, Ozawa Y, Fukuda T, Tanaka M, Sawa M, Takada S, Yoshida S, Kimura T, Ichinohe T, Atsuta Y, Kanda J; Donor/Source Working Group of the Japan Society for Hematopoietic Cell Transplantation.	Biol Blood Marrow Transplant	2020	26(11):21 05-14.	WGP 18-14
289	Outcomes of third allogeneic hematopoietic stem cell transplantation in relapsed/refractory acute leukemia after a second transplantation.	Kobayashi S, Kanda Y, Konuma T, Inamoto Y, Matsumoto K, Uchida N, Ikegame K, Miyamoto T, Doki N, Nakamae H, Katayama Y, Takahashi S, Shiratori S, Saito S, Kawakita T, Kanda J, Fukuda T, Atsuta Y, Kimura F.	Bone Marrow Transplant	2022	57(1):43- 50.	WGP 18-15

290	The impact of GVHD on outcomes after adult single cord blood transplantation in European and Japanese populations.	Kanda J, Hayashi H, Ruggeri A, Kimura F, Volt F, Takahashi S, Kako S, Tozatto-Maio K, Yanada M, Sanz G, Uchida N, Angelucci E, Kato S, Mohty M, Forcade E, Tanaka M, Sierra J, Ohta T, Saccardi R, Fukuda T, Ichinohe T, Kimura T, Rocha V, Okamoto S, Nagler A, Atsuta Y, Gluckman E.	Bone Marrow Transplant	2022	57(1):57-64.	WGP 18-16
291	Impact of donor types on reduced-intensity conditioning allogeneic stem cell transplant for mature lymphoid malignancies.	Imahashi N, Terakura S, Kondo E, Kato K, Kim SW, Shinohara A, Watanabe M, Fukuda T, Uchida N, Kobayashi H, Ishikawa J, Kataoka K, Shiratori S, Ikeda T, Matsuoka KI, Yoshida S, Kondo T, Kimura T, Onizuka M, Ichinohe T, Atsuta Y, Kanda J.	Bone Marrow Transplant	2022	57(2):243-51.	WGP 18-17
292	Differential Effect of Graft-versus-Host Disease on Survival in Acute Leukemia according to Donor Type.	Konuma T, Kanda J, Kuwatsuka Y, Yanada M, Kondo T, Hirabayashi S, Kako S, Akahoshi Y, Uchida N, Doki N, Ozawa Y, Tanaka M, Eto T, Sawa M, Yoshioka S, Kimura T, Kanda Y, Fukuda T, Atsuta Y, Kimura F.	Clin Cancer Res	2021	27(17):4825-35.	WGP 18-18
293	HLA 1-3 antigen-mismatched related peripheral blood stem cells transplantation using low-dose antithymocyte globulin versus unrelated cord blood transplantation.	Wada F, Watanabe M, Konuma T, Okabe M, Kobayashi S, Uchida N, Ikegame K, Tanaka M, Sugio Y, Mukae J, Onizuka M, Kawakita T, Kuriyama T, Takahashi S, Fukuda T, Nakano N, Sawa M, Kimura T, Ichinohe T, Atsuta Y, Kanda J; Donor/Source Working Group of the Japan Society for Hematopoietic Cell Transplantation.	Am J Hematol	2022	97(3):311-21.	WGP 18-19
294	Clinical factors predicting the response of acute graft-versus-host disease to corticosteroid therapy: an analysis from the GVHD Working Group of the Japan Society for Hematopoietic Cell Transplantation.	Murata M, Nakasone H, Kanda J, Nakane T, Furukawa T, Fukuda T, Mori T, Taniguchi S, Eto T, Ohashi K, Hino M, Inoue M, Ogawa H, Atsuta Y, Nagamura-Inoue T, Yabe H, Morishima Y, Sakamaki H, Suzuki R.	Biol Blood Marrow Transplant	2013	19(8):1183-9.	WGP 19-1
295	A case-control study of bronchiolitis obliterans syndrome following allogeneic hematopoietic stem cell transplantation.	Nakasone H, Kanda J, Yano S, Atsuta Y, Ago H, Fukuda T, Kakihana K, Adachi T, Yujiri T, Taniguchi S, Taguchi J, Morishima Y, Nagamura T, Sakamaki H, Mori T, Murata M; GVHD Working Group of the Japan Society for Hematopoietic Cell Transplantation.	Transpl Int	2013	26(6):631-9.	WGP 19-2
296	Risk factors and organ involvement of chronic GVHD in Japan.	Kanda J, Nakasone H, Atsuta Y, Toubai T, Yokoyama H, Fukuda T, Taniguchi S, Ohashi K, Ogawa H, Eto T, Miyamura K, Morishima Y, Nagamura-Inoue T, Sakamaki H, Murata M.	Bone Marrow Transplant	2014	49(2):228-35.	WGP 19-3
297	Impact of conditioning intensity and TBI on acute GVHD after hematopoietic cell transplantation.	Nakasone H, Fukuda T, Kanda J, Mori T, Yano S, Kobayashi T, Miyamura K, Eto T, Kanamori H, Iwato K, Uchida N, Mori S, Nagamura-Inoue T, Ichinohe T, Atsuta Y, Teshima T, Murata M; GVHD working group of the Japan Society of Hematopoietic Cell Transplantation.	Bone Marrow Transplant	2015	50(4):559-65.	WGP 19-4
298	Age influences post-graft-versus-host disease non-relapse mortality in adults with acute graft-versus-host disease of varying severity following allogeneic hematopoietic cell transplant.	Nakane T, Fukuda T, Kanda J, Taniguchi S, Eto T, Ohashi K, Nakamae H, Kurokawa M, Mori T, Morishima Y, Nagamura-Inoue T, Sakamaki H, Atsuta Y, Murata M.	Leuk Lymphoma	2015	56(8):2392-7.	WGP 19-5
299	Comparison of continuous and twice-daily infusions of cyclosporine A for graft-versus-host-disease prophylaxis in pediatric hematopoietic stem cell transplantation.	Umeda K, Adachi S, Tanaka S, Ogawa A, Hatakeyama N, Kudo K, Sakata N, Igarashi S, Ohshima K, Hyakuna N, Chin M, Goto H, Takahashi Y, Azuma E, Koh K, Sawada A, Kato K, Inoue M, Atsuta Y, Takami A, Murata M; on behalf of the GVHD Working Group of the Japan Society for Hematopoietic Cell Transplantation.	Pediatr Blood Cancer	2015	62(2):291-8.	WGP 19-6

300	A comparison of tacrolimus and cyclosporine combined with methotrexate for graft-versus-host disease prophylaxis, stratified by stem cell source: a retrospective nationwide survey.	Sakai R, Taguri M, Oshima K, Mori T, Ago H, Adachi S, Morita S, Taniguchi S, Fukuda T, Ohashi K, Eto T, Miyamura K, Iwato K, Kobayashi N, Kanamori H, Morishima Y, Nagamura-Inoue T, Sakamaki H, Atsuta Y, Murata M.	Int J Hematol	2016	103(3):322-33.	WGP 19-7
301	Risk factors and prognosis of hepatic acute GvHD after allogeneic hematopoietic cell transplantation.	Arai Y, Kanda J, Nakasone H, Kondo T, Uchida N, Fukuda T, Ohashi K, Kaida K, Iwato K, Eto T, Kanda Y, Nakamae H, Nagamura-Inoue T, Morishima Y, Hirokawa M, Atsuta Y, Murata M.	Bone Marrow Transplant	2016	51(1):96-102.	WGP 19-8
302	Impact of graft-versus-host disease on outcomes after unrelated cord blood transplantation.	Kanda J, Morishima Y, Terakura S, Wake A, Uchida N, Takahashi S, Ono Y, Onishi Y, Kanamori H, Aotsuka N, Ozawa Y, Ogawa H, Sakura T, Ohashi K, Ichinohe T, Kato K, Atsuta Y, Teshima T, Murata M.	Leukemia	2017	31(3):663-8.	WGP 19-9
303	Low-dose thymoglobulin as second-line treatment for steroid-resistant acute GvHD: an analysis of the JSHCT.	Murata M, Ikegame K, Morishita Y, Ogawa H, Kaida K, Nakamae H, Ikeda T, Nishida T, Inoue M, Eto T, Kubo K, Sakura T, Mori T, Uchida N, Ashida T, Matsuhashi Y, Miyazaki Y, Ichinohe T, Atsuta Y, Teshima T.	Bone Marrow Transplant	2017	52(2):252-7.	WGP 19-10
304	Exploratory research for optimal GvHD prophylaxis after single unit CBT in adults: short-term methotrexate reduced the incidence of severe GvHD more than mycophenolate mofetil.	Terakura S, Wake A, Inamoto Y, Murata M, Sakai R, Yamaguchi T, Takahashi S, Uchida N, Onishi Y, Ohashi K, Ozawa Y, Kanamori H, Yamaguchi H, Fukuda T, Ichinohe T, Takanashi M, Atsuta Y, Teshima T.	Bone Marrow Transplant	2017	52(3):423-30.	WGP 19-11
305	Comparison of graft-versus-host disease-free, relapse-free survival according to a variety of graft sources: antithymocyte globulin and single cord blood provide favorable outcomes in some subgroups.	Inamoto Y, Kimura F, Kanda J, Sugita J, Ikegame K, Nakasone H, Nannya Y, Uchida N, Fukuda T, Yoshioka K, Ozawa Y, Kawano I, Atsuta Y, Kato K, Ichinohe T, Inoue M, Teshima T; JSHCT GVHD Working Group.	Haematologica	2016	101(12):1592-602.	WGP 19-12
306	Allogeneic unrelated bone marrow transplantation from older donors results in worse prognosis in recipients with aplastic anemia.	Arai Y, Kondo T, Yamazaki H, Takenaka K, Sugita J, Kobayashi T, Ozawa Y, Uchida N, Iwato K, Kobayashi N, Takahashi Y, Ishiyama K, Fukuda T, Ichinohe T, Atsuta Y, Mori T, Teshima T; Japan Society for Hematopoietic Cell Transplantation.	Haematologica	2016	101(5):644-52.	WGP 19-13
307	GvHD prophylaxis after single-unit reduced intensity conditioning cord blood transplantation in adults with acute leukemia.	Terakura S, Kuwatsuka Y, Yamasaki S, Wake A, Kanda J, Inamoto Y, Mizuta S, Yamaguchi T, Uchida N, Kouzai Y, Aotsuka N, Ogawa H, Kanamori H, Nishiwaki K, Miyakoshi S, Onizuka M, Amano I, Fukuda T, Ichinohe T, Atsuta Y, Murata M, Teshima T.	Bone Marrow Transplant	2017	52(9):1261-7.	WGP 19-14
308	Impacts of thymoglobulin in patients with acute leukemia in remission undergoing allogeneic HSCT from different donors.	Wakamatsu M, Terakura S, Ohashi K, Fukuda T, Ozawa Y, Kanamori H, Sawa M, Uchida N, Ota S, Matsushita A, Kanda Y, Nakamae H, Ichinohe T, Kato K, Murata M, Atsuta Y, Teshima T; GVHD Working Group of the Japan Society for Hematopoietic Cell Transplantation.	Blood Advances	2019	3(2):105-15.	WGP 19-15
309	Effect of Graft-Versus-Host Disease on Outcomes After Pediatric Single Cord Blood Transplantation.	Kanda J, Umeda K, Kato K, Murata M, Sugita J, Adachi S, Koh K, Noguchi M, Goto H, Yoshida N, Sato M, Koga Y, Hori T, Cho Y, Ogawa A, Inoue M, Hashii Y, Atsuta Y, Teshima T; JSHCT GVHD Working Group.	Bone Marrow Transplant	2020	55(7):1430-7.	WGP 19-16

310	Effect of methotrexate dose in graft-versus-host disease prophylaxis after single-unit cord blood transplantation in adult acute myeloid leukemia.	Terakura S, Kuwatsuka Y, Sugita J, Takahashi S, Ozawa Y, Ozeki K, Yoshioka S, Nakamae H, Kawakita T, Sawa M, Morishige S, Najima Y, Katsuoka Y, Sakaida E, Kouzai Y, Kimura T, Ichinohe T, Fukuda T, Atsuta Y, Murata M, Teshima T.	Int J Hematol	2021	113(6):84 0-50.	WGP 19-17
311	Off-the-shelf bone marrow-derived mesenchymal stem cell treatment for acute graft-versus-host disease: real-world evidence.	Murata M, Terakura S, Wake A, Miyao K, Ikegame K, Uchida N, Kataoka K, Miyamoto T, Onizuka M, Eto T, Doki N, Ota S, Sato M, Hashii Y, Ichinohe T, Fukuda T, Atsuta Y, Okamoto S, Teshima T.	Bone Marrow Transplant	2021	56(10):23 55-66.	WGP 19-18
312	Impact of hepatitis C virus infection on clinical outcome in recipients after allogeneic hematopoietic cell transplantation.	Nakasone H, Kurosawa S, Yakushijin K, Taniguchi S, Murata M, Ikegame K, Kobayashi T, Eto T, Miyamura K, Sakamaki H, Morishima Y, Nagamura T, Suzuki R, Fukuda T.	Am J Hematol	2013	88(6):477 -84.	WGP 20-1
313	Pre-transplant risk factors for cryptogenic organizing pneumonia/bronchiolitis obliterans organizing pneumonia after hematopoietic cell transplantation.	Nakasone H, Onizuka M, Suzuki N, Fujii N, Taniguchi S, Kakahana K, Ogawa H, Miyamura K, Eto T, Sakamaki H, Yabe H, Morishima Y, Kato K, Suzuki R, Fukuda T.	Bone Marrow Transplant	2013	48(10):13 17-23.	WGP 20-2
314	Salvage allogeneic hematopoietic SCT for primary graft failure in children.	Kato M, Matsumoto K, Suzuki R, Yabe H, Inoue M, Kigasawa H, Inagaki J, Koh K, Hashii Y, Tauchi H, Suminoe A, Kikuta A, Sakamaki H, Kawa K, Kato K, Fukuda T.	Bone Marrow Transplant	2013	48(9):117 3-8.	WGP 20-3
315	Impact of pretransplant body mass index on the clinical outcome after allogeneic hematopoietic SCT.	Fuji S, Takano K, Mori T, Eto T, Taniguchi S, Ohashi K, Sakamaki H, Morishima Y, Kato K, Miyamura K, Suzuki R, Fukuda T.	Bone Marrow Transplant	2014	49(12):15 05-12.	WGP 20-4
316	Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.	Takenaka K, Nishida T, Asano-Mori Y, Oshima K, Ohashi K, Mori T, Kanamori H, Miyamura K, Kato C, Kobayashi N, Uchida N, Nakamae H, Ichinohe T, Morishima Y, Suzuki R, Yamaguchi T, Fukuda T.	Biol Blood Marrow Transplant	2015	21(11):20 08-16.	WGP 20-5
317	Pre-transplant diabetes mellitus is a risk factor for non-relapse mortality, especially infection-related mortality, after allogeneic hematopoietic SCT.	Takano K, Fuji S, Uchida N, Ogawa H, Ohashi K, Eto T, Sakamaki H, Morishima Y, Kato K, Suzuki R, Fukuda T.	Bone Marrow Transplant	2015	50(4):553 -8.	WGP 20-6
318	Sinusoidal obstruction syndrome after allogeneic hematopoietic stem cell transplantation: Incidence, risk factors and outcomes.	Yakushijin K, Atsuta Y, Doki N, Yokota A, Kanamori H, Miyamoto T, Ohwada C, Miyamura K, Nawa Y, Kurokawa M, Mizuno I, Mori T, Onizuka M, Taguchi J, Ichinohe T, Yabe H, Morishima Y, Kato K, Suzuki R, Fukuda T.	Bone Marrow Transplant	2016	51(3):403 -9.	WGP 20-7
319	Donor cell-derived hematologic malignancy: A survey by the Japan society for hematopoietic cell transplantation.	Kato M, Yamashita T, Suzuki R, Matsumoto K, Nishimori H, Takahashi S, Iwato K, Nakaseko C, Kondo T, Imada K, Kimura F, Ichinohe T, Hashii Y, Kato K, Atsuta Y, Taniguchi S, Fukuda T.	Leukemia	2016	30(8):174 2-5.	WGP 20-8
320	Impact of total body irradiation on successful neutrophil engraftment in unrelated bone marrow or cord blood transplantation.	Nakasone H, Fuji S, Yakushijin K, Onizuka M, Shinohara A, Ohashi K, Miyamura K, Uchida N, Takanashi M, Ichinohe T, Atsuta Y, Fukuda T, Ogata M; Complication Working Group of Japanese Society for Hematopoietic Cell Transplantation.	Am J Hematol	2017	92(2):171 -8.	WGP 20-9
321	Clinical characteristics and outcome of human herpesvirus-6 encephalitis after allogeneic hematopoietic stem cell transplantation.	Ogata M, Oshima K, Ikebe T, Takano K, Kanamori H, Kondo T, Ueda Y, Mori T, Hashimoto H, Ogawa H, Eto T, Ueki T, Miyamoto T, Ichinohe T, Atsuta Y, Fukuda T.	Bone Marrow Transplant	2017	52(11):15 63-70.	WGP 20-10

322	BM is preferred over PBSCs in transplantation from an HLA-matched related female donor to a male recipient.	Nakasone H, Kawamura K, Yakushijin K, Shinohara A, Tanaka M, Ohashi K, Ota S, Uchida N, Fukuda T, Nakamae H, Matsuoka KI, Kanda J, Ichinohe T, Atsuta Y, Inamoto Y, Seo S, Kimura F, Ogata M.	Blood Advances	2019	3(11):175 0-60.	WGP 20-11
323	Clinical course of autologous recovery with chromosomal abnormalities after allogeneic hematopoietic stem cell transplantation.	Kato M, Nakasone H, Nakano N, Fuji S, Shinohara A, Yokoyama H, Sakashita K, Hori T, Takahashi S, Nara M, Kanda Y, Mori T, Takita J, Kawaguchi H, Kawakita T, Ichinohe T, Fukuda T, Atsuta Y, Ogata M; Transplantation Complication Working Group of the Japan Society for Hematopoietic Cell Transplantation.	Bone Marrow Transplant	2020	55(6):102 3-8.	WGP 20-12
324	Risk Factors and Predictive Scoring System For Post-Transplant Lymphoproliferative Disorder after Hematopoietic Stem Cell Transplantation.	Fujimoto A, Hiramoto N, Yamasaki S, Inamoto Y, Uchida N, Maeda T, Mori T, Kanda Y, Kondo T, Shiratori S, Miyakoshi S, Ishiyama K, Ikegame K, Matsuhashi Y, Tanaka J, Ichinohe T, Atsuta Y, Ogata M, Suzuki R.	Biol Blood Marrow Transplant	2019	25(7):144 1-9.	WGP 20-13
325	Low incidence of post-transplant lymphoproliferative disorder after allogeneic stem cell transplantation in patients with lymphoma treated with rituximab.	Fujimoto A, Hiramoto N, Yamasaki S, Inamoto Y, Ogata M, Sugio Y, Fukuda T, Uchida N, Ikegame K, Matsuoka KI, Shiratori S, Kondo T, Miyamoto T, Eto T, Ichinohe T, Kanda Y, Atsuta Y, Suzuki R; Complication Working Group of the Japan Society for Hematopoietic Cell Transplantation.	Hematologica Oncology	2020	38(2):146 -52.	WGP 20-14
326	Impact of pretransplant donor-specific anti-HLA antibodies on cord blood transplantation on behalf of the Transplant Complications Working Group of Japan Society for Hematopoietic Cell Transplantation.	Fuji S, Oshima K, Ohashi K, Sawa M, Saito T, Eto T, Tanaka M, Onizuka M, Nakamae H, Shiratori S, Ozawa Y, Hidaka M, Nagamura-Inoue T, Tanaka H, Fukuda T, Ichinohe T, Atsuta Y, Ogata M.	Bone Marrow Transplant	2020	55(4):722 -8.	WGP 20-15
327	Comparison of the outcomes after haploidentical and cord blood salvage transplantations for graft failure following allogeneic hematopoietic stem cell transplantation.	Harada K, Fuji S, Seo S, Kanda J, Ueki T, Kimura F, Kato K, Uchida N, Ikegame K, Onizuka M, Matsuoka KI, Doki N, Kawakita T, Onishi Y, Yano S, Fukuda T, Takanashi M, Kanda Y, Atsuta Y, Ogata M; transplant complications working group of the Japan Society for Hematopoietic Cell Transplantation.	Bone Marrow Transplant	2020	55(9):178 4-95.	WGP 20-16
328	Comparison of immunosuppressant regimens in salvage cord blood transplantation for graft failure after allogeneic hematopoietic stem cell transplantation.	Harada K, Fuji S, Seo S, Uchida N, Kawakita T, Yano S, Ozawa Y, Yoshioka S, Onishi Y, Noguchi Y, Onizuka M, Matsuhashi Y, Kimura T, Ichinohe T, Atsuta Y; Transplant Complications Working Group of the Japan Society for Hematopoietic Cell Transplantation; GVHD Working Group of the Japan Society for Hematopoietic Cell Transplantation, Terakura S, Nakasone H.	Bone Marrow Transplant	2021	56(2):400 -10.	WGP 20-17
329	Severe acute graft-versus-host disease increases the incidence of blood stream infection and mortality after allogeneic hematopoietic cell transplantation: Japanese transplant registry study.	Inoue Y, Okinaka K, Fuji S, Inamoto Y, Uchida N, Toya T, Ikegame K, Eto T, Ozawa Y, Iwato K, Kanda Y, Atsuta Y, Ogata M, Fukuda T; Transplant Complications Working Group of The Japan Society for Hematopoietic Cell Transplantation.	Bone Marrow Transplant	2021	56(9):212 5-36.	WGP 20-18
330	Effect of cytomegalovirus reactivation with or without acute graft-versus-host disease on the risk of nonrelapse mortality.	Akahoshi Y, Kimura SI, Inamoto Y, Seo S, Muranushi H, Shimizu H, Ozawa Y, Tanaka M, Uchida N, Kanda Y, Katayama Y, Shiratori S, Ota S, Matsuoka KI, Onizuka M, Fukuda T, Atsuta Y, Murata M, Terakura S, Nakasone H.	Clin Infect Dis	2021	73(3):e62 0-8.	WGP 20-19

331	Cytomegalovirus reactivation is associated with an increased risk of late-onset invasive aspergillosis independently of grade II–IV acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation: JSTCT Transplant Complications Working Group.	Kimura SI, Tamaki M, Okinaka K, Seo S, Uchida N, Igarashi A, Ozawa Y, Ikegame K, Eto T, Tanaka M, Shiratori S, Nakamae H, Sawa M, Kawakita T, Onizuka M, Fukuda T, Atsuta Y, Kanda Y, Nakasone H.	Ann Hematol	2021	100(12):3029–38.	WGP 20–20
332	Prognostic factors in salvage transplantation for graft failure following allogeneic hematopoietic stem cell transplantation.	Harada K, Kimura SI, Fuji S, Najima Y, Yakushijin K, Uchida N, Onizuka M, Ikegame K, Yano S, Shingai N, Matsuoka KI, Onishi Y, Sawa M, Takada S, Kawakita T, Fukuda T, Kanda J, Atsuta Y, Nakasone H.	Bone Marrow Transplant	2021	56(9):2183–93.	WGP 20–21
333	Cytomegalovirus gastroenteritis in patients with acute graft-versus-host disease.	Akahoshi Y, Kimura SI, Tada Y, Matsukawa T, Tamaki M, Doki N, Uchida N, Tanaka M, Nakamae H, Kuriyama T, Matsuoka KI, Ikeda T, Kimura T, Fukuda T, Kanda Y, Atsuta Y, Murata M, Terakura S, Nakasone H.	Blood Advances	2022	25;6(2):574–84.	WGP 20–22
334	Risk and Predictive Factors for Candidemia After Allogeneic Hematopoietic Cell Transplantation: JSTCT Transplant Complications Working Group.	Kimura SI, Kameda K, Harada K, Saburi M, Okinaka K, Shinohara A, Uchida N, Nishijima A, Ozawa Y, Tanaka M, Kuriyama T, Katayama Y, Sawa M, Ikegame K, Kawakita T, Kanda Y, Nakamae H, Ara T, Kimura T, Sato A, Fukuda T, Atsuta Y, Nakasone H.	Transplant Cell Ther		in press	WGP 20–23
335	Late Mortality and Causes of Death among Long-Term Survivors after Allogeneic Stem Cell Transplantation.	Atsuta Y, Hirakawa A, Nakasone H, Kurosawa S, Oshima K, Sakai R, Ohashi K, Takahashi S, Mori T, Ozawa Y, Fukuda T, Kanamori H, Morishima Y, Kato K, Yabe H, Sakamaki H, Taniguchi S, Yamashita T; Late Effect and Quality of Life Working Group of the Japan Society for Hematopoietic Cell Transplantation.	Biol Blood Marrow Transplant	2016	22(9):1702–9.	WGP 21–1
336	Outcomes of patients who developed subsequent solid cancer after hematopoietic cell transplantation.	Inamoto Y, Matsuda T, Tabuchi K, Kurosawa S, Nakasone H, Nishimori H, Yamasaki S, Doki N, Iwato K, Mori T, Takahashi S, Yabe H, Kohno A, Nakamae H, Sakura T, Hashimoto H, Sugita J, Ago H, Fukuda T, Ichinohe T, Atsuta Y, Yamashita T; Japan Society for Hematopoietic Cell Transplantation Late Effects and Quality of Life Working Group.	Blood Advances	2018	2(15):1901–13.	WGP 21–2
337	Characterization of myeloid neoplasms following allogeneic hematopoietic cell transplantation.	Kuno M, Yamasaki S, Fujii N, Ishida Y, Fukuda T, Kataoka K, Uchida N, Katayama Y, Sato M, Onai D, Miyamoto T, Ota S, Yoshioka S, Ara T, Hangaishi A, Hashii Y, Onizuka M, Ichinohe T, Atsuta Y, Inamoto Y; on behalf of the Japan Society for Hematopoietic Cell Transplantation Late Effects and Quality of Life Working Group.	Am J Hematol	2022	97(2):185–93.	WGP 21–3
338	Late mortality and causes of death among long-term survivors after autologous hematopoietic stem cell transplantation.	Iida M, Nakasone H, Yamashita T, Inoue M, Ishida Y, Uchiyama H, Katayama Y, Miyamoto T, Yoshioka S, Shiratori S, Mori T, Sawa M, Sugio Y, Fukuda T, Ichinohe T, Atsuta Y, Inamoto Y, for the Late Effect and Quality of Life Working Group of the Japan Society for Hematopoietic Cell Transplantation.	Blood Cell Therapy	2020	3:11–7.	WGP 21–4